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(Under the direction of Marisa Domino) 
 
Parkinson’s disease (PD) is a chronic, progressive disorder associated with high 
costs of care and morbidity. The disease affects patients’ motor skills, but also is 
associated non-motor effects such as depression. The complexity of PD requires a 
multidisciplinary, coordinated, patient-centered model of care. The objective of this 
study is to estimate the effects of patient-centered medical homes (PCMH) on 
healthcare costs and outcomes for medical beneficiaries with PD and those with PD and 
depression in the US. 
Using instrumental variable techniques to address for PCMH selection bias and 
generalized estimating equations models to account for repeated observations, we 
estimated the effect of PCMH on outpatient research utilization, hospitalizations, and 
costs in two cohorts of Medicare beneficiaries: those with PD, and those with PD and 
comorbid depression. The key explanatory variable was receipt of care from a PCMH 
provider. We considered Medicare claims for individuals with PD from 2007-2013 
merged with National Committee for Quality Assurance (NCQA) provider recognition 
status. Finally, we explored the heterogeneity of PCMH treatment effect on resource 
use and outcomes via person-centered treatment effects. 
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We found that PCMH participation significantly increased the utilization outpatient 
services among beneficiaries with PD (neurologist visits, physical/occupational therapy, 
and speech therapy). PCMH also led to a significant reduction in hospitalizations for 
falls and for pneumonia/aspiration pneumonia. No significant differences in total 
Medicare costs were observed. In beneficiaries with PD and depression, we found that 
PCMH participation led to an increase in psychotherapy use and a decrease in receipt 
of contraindicated medications. No significant differences were found in antidepressant 
use or hospitalizations for depression or suicidal behavior. Again, we found no 
significant differences in total Medicare costs. Finally, we observed heterogeneity of 
treatment effect, most notably that the treatment effect of PCMH was greater for those 
who did not receive treatment than for those who did.  
Our findings suggest that the PCMH model provides significant benefits in terms of 
quality of care. However, the PCMH model may not be identifying the patients who 
would benefit most from treatment. Decision-makers should consider this heterogeneity 
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CHAPTER 1: INTRODUCTION 
Parkinson’s Disease 
Parkinson’s disease (PD) is a movement disorder involving the death of neurons in 
the brain. The disease is chronic and progressive in nature and affects nearly one 
million people in the United States. The disease is very prevalent in the elderly: nearly 
500,000 patients over the age of 65 have the disease (1).  As with many chronic, 
progressive diseases, individuals with PD are more likely to require physician visits, 
emergency department (ED) visits, home health care, and long-term care than those 
without PD (2). The overall burden of PD in the US is estimated to be around $15 million 
annually, or over $20,000 per patient per year (3). Due to the aging of the US 
population, the prevalence of PD is expected to double in the next 15 years, which will 
only exacerbate the economic impact of the disease, especially in terms of total costs to 
Medicare (4). 
The most easily recognized symptoms of PD are motor symptoms. These 
symptoms include tremors, bradykinesia (slow movement), and rigidity of limbs (5). 
However, beyond the motor symptoms PD has several non-motor symptoms. These 
include sleep disorders, fatigue, constipation, sensory dysfunction, loss of appetite, 
cognitive deficits, anxiety, and depression (5).  About half or more of all PD patients will 
develop depression in their lifetime (6,7).  Among patients with PD, depression has 
been found to be one of the major predictors of health care services use (8). 
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There is currently no cure for PD, and treatment of the disease involves 
management of the symptoms. Pharmacotherapy is administered to manage the motor 
symptoms of the disease. Dopamine agonists are generally used in early stages of the 
disease, whereas levodopa is the gold standard in more advanced stages of the 
disease (9). However, these drugs do not resolve the underlying condition, and none is 
uniformly or permanently effective. Eventually, patients may require combination of 
these drugs, and dose escalation may be necessary over time. Additionally, prolonged 
use of levodopa can lead to dyskinesia over time (9). 
Because PD currently has no cure, and because the disease can manifest both in 
terms of motor symptoms and non-motor symptoms, care for the disease requires an 
integrated, interdisciplinary patient-centered plan of care and a multidisciplinary team of 
providers that collaborates jointly with the patient to determine the optimal care plan for 
the patient (10). Despite this need, there have been few attempts at developing an 
integrated care model for PD. The Netherlands has been the setting of two such 
experiments: ParkinsonNet and IMPACT (11–13). ParkinsonNet is a national 
collaborative of physicians and other health professionals in the Netherlands to develop 
evidenced-based practices and to educate providers in the multidisciplinary care for PD.  
The IMPACT study was a smaller study in which patients were offered “individually 
tailored comprehensive assessment in an expert tertiary referral center and subsequent 
referrals to a regional network of allied health professionals specialized in Parkinson's 
disease” (13). However, neither of these studies has shown substantively positive 
results to date. Other forms of care that have proven more effective have been palliative 
care and hospice care (10). However, these modes of care are tailored to end-of-life 
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patients, whereas much of the PD care pathway occurs well before patients reach the 
need for end-of-life care. 
Medical Homes 
The medical home model is a concept of health care that focuses on patient-
centered, comprehensive patient care, with a goal of improved quality of health care in 
the US.  It is not a novel concept, as the origins of the medical home date back to at 
least 1967 with the American Academy of Pediatrics’ Standards of Child Health Care 
(14). More recently, the Agency for Healthcare Research and Quality (AHRQ) defined 
the medical home to cover the following five functions/attributes (15): 
• Comprehensive care provided through a team of care providers including 
physicians, nurses, pharmacists, nutritionists, social workers, educators, etc.; 
• Patient-centered focus built on relationship-based, holistic care of the patient; 
• Coordinated care in which a strong level of communication is fostered between 
the patient, family, and care providers; 
• Better access to services, including greater hours, anytime support via telephone 
or electronic access, shorter waiting times, etc.; and ultimately 
• Improved quality and safety. 
In addition to the AHRQ definition, several organizations have their own definitions 
for medical homes, including the American Academy of Pediatrics, the American 
Academy of Family Physicians, and the National Committee for Quality Assurance 
(NCQA) (16). The common theme of these definitions consists of comprehensive care 
focused on improving quality of care.  
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Beginning in 2008, the NCQA developed a set of standards for earning recognition 
as a medical home. These standards include improving access, providing self-care 
support and resources, measuring and improving performance, coordinating care, 
identifying and managing populations, and management of care.  The three levels of 
recognition (1-3) are achieved based on total scores in each of the elements. Though 
several other national accreditation programs exist (17,18), the NCQA is the most 
widely adopted approach taken by practices seeking recognition as a medical home, 
with over 13,000 practices and nearly 67,000 physicians recognized (19). 
Several studies of the general impact of patient-centered medical homes (PCMH) 
on health care and costs have been conducted, with varying results. A systematic 
review of research on the effects of PCMH found some limited evidence that PCMH 
participation may lead to fewer emergency room visits, most notably in the elderly 
(20,21). Some evidence suggests that PCMH leads to better patient satisfaction (22). 
Reid and colleagues (22) also found that PCMH care reduced inpatient stays, 
emergency department visits, and per-patient costs. Friedberg and colleagues (23) 
found little benefit of medical homes based on a propensity score matching method 
analyzing medical data from a pre-post study design. Flottemesch and colleagues (24) 
found that the benefit of medical homes may be limited to complex patients. 
Christensen and colleagues (25) found that the Walter Reed PCMH reduced costs in 
patients with and without chronic conditions, but the relative cost-savings were greater 
in patients with chronic conditions. More recent research has also shown medical 
homes may be particularly beneficial for those with complex medical conditions, 
although participation among patients with psychosis may be less than optimal (26–30). 
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The results of these studies suggest a similar theme: the greatest value of medical 
homes appears to be for those with complex conditions.  
Potential Impact of Medical Homes on Patients with Parkinson’s Disease and 
Depression 
Because of the complex and comprehensive nature of the disease, researchers 
suggest that PD patients require a multidisciplinary team (docs, pharmacists, nurses, 
physiotherapists) to manage the disease (31–33). Ideally, comprehensive care should 
be accessible in the patients’ local community. Individuals with PD also need 
personalized care patterns in response to the progression of the disease, as the 
disease progresses differently in each patient (10).  Additionally, increased 
dissemination of information on PD and services available is recommended.  
The success of the integrative care seen in palliative care and hospice care (which 
are inherently designed as interdisciplinary, coordinated, patient-centered care) 
combined with the comprehensive nature of PD do suggest the potential benefit of the 
medical homes model. The medical homes model is developed with the specific 
intention to address many of the issues in care that face patients with PD. The 
coordination of care is a critical component of the medical homes model. Additionally, 
the focus on comprehensive care and improvements in access are critical features that 
would be beneficial in the care for PD patients. Given the characteristics of the medical 
homes model, this approach to care may result in improvement in care for patients with 
PD. I provide further detail of the theoretical benefit of the medical home in Chapter 2. 
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Significance 
This study provides information about the value of medical homes both to the 
patient and health care system, for individuals with PD as well as for those with PD and 
depression. It is, to my knowledge, the first such study estimating the effects of medical 
homes on care for these individuals. In addition to making an initial exploration into the 
effects of PCMH on those with PD, in Aim 3 I examine patient-centered treatment 
effects of medical homes. This methodology allows me to determine if there is 
significant heterogeneity in the effect of PCMH participation on outcomes, as well as to 
identify those patient characteristics for which medical homes participation may provide 
the most value. The results of these analyses add to the understanding of the impact of 
the medical homes model on patients with complex conditions, as well as illustrate the 
economic value of the medical home in terms of patient welfare and efficient allocation 
of resources. 
Study Aims and Hypotheses 
To examine the effect of PCMH participation on quality of care and health outcomes 
for Medicare beneficiaries with PD, I conducted retrospective database analyses using 
Medicare claims data to address three aims. The aims, as well as the research 
hypotheses for these aims, can be seen below: 
Aim 1: Estimate the effect of PCMH participation annual use of outpatient 
care, health outcomes, and total annual Medicare costs among Medicare 
beneficiaries with PD.  
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Hypothesis 1.1: PCMHs will lead to a higher probability of receiving of guideline-
recommended outpatient care (neurologist visits, physical/occupational therapy, speech 
therapy) compared to other models of primary care.  
Hypothesis 1.2: PCMHs will lead to fewer hospitalized falls and aspiration 
pneumonia cases compared with other models of primary care.  
Hypothesis 1.3: PCMH participation will result in no difference or a reduction in total 
Medicare costs.  
Aim 2: Estimate the effect of PCMH participation annual use of outpatient 
depression care services, depression health outcomes, and total annual Medicare 
costs among Medicare beneficiaries with PD and comorbid depression.  
Hypothesis 2.1: PCMHs will lead to a higher probability of receiving of guideline-
recommended outpatient care (psychotherapy, antidepressant use) compared to other 
models of primary care.  
Hypothesis 2.2: PCMHs will lead to a lower probability of receiving of medications 
contraindicated with PD medication as compared with other models of primary care.  
Hypothesis 2.3: PCMHs will lead to fewer hospitalized depressive episodes and 
fewer hospitalizations for suicidal behavior compared with other models of primary care.  
Hypothesis 2.4: PCMH participation will result in no difference or a reduction in total 
Medicare costs. 
Aim 3: Examine the heterogeneity of treatment effect for PCMH participation 
among Medicare beneficiaries with PD.  
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Hypothesis 3.1: PCMH participation will have a heterogeneous treatment effect 
such that the treatment effect on the treated (those participating in PCMH) is 
significantly different than the treatment effect on the untreated. 
Hypothesis 3.2: PCMH participation will have a heterogeneous treatment effect 
such that those with comorbidities such as depression will have a higher treatment 





CHAPTER 2: CONCEPTUAL FRAMEWORK 
In this section, I outline first the economic framework driving the decision to receive 
health care, and then the economics motivating the choice of a PCMH provider, as I 
view this as conceptually a two-step decision. For the purposes of this study, the 
second part (the choice of provider) is of most interest, as patients with PD are more 
likely to need care than the average person. 
Decision to consume health care 
When considering the economic implications of seeking any health care, I first refer 
to the classic model proposed by Grossman (34) as a framework for an individual’s 
health production.  In this model, individuals choose a level of healthcare consumption 
to optimize their lifetime utility based on the following intertemporal utility function: 
U = U(C0H0,…,CnHn,Z0,…,Zn) 
Where CiHi represents consumption of health services in year i and Zi represents total 
consumption of other commodities in year i.  Other commodities may include leisure 
activities, contributions to human capital such as education, and contribution to financial 
resources via time spent at work.   
The consumption of health services and other commodities are subject to time and 
budget constraints, so investments in health capital each year come at the expense of 
investments in consumption of leisure goods in that year.  However, gains in human 
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capital from health investments in previous years may have an impact on the utility 
gained from leisure goods consumed in future years. As such, there is an intertemporal 
utility tradeoff gain from investment in health services. This tradeoff can be thought of 
more simply as “by devoting some time and money to healthcare today, I’ll be healthier 
and able to do more and enjoy more tomorrow.” The individual must thus choose the 
optimal consumption of health care services and other commodities each year to 
maximize lifetime utility. 
In the case of patients with PD, the marginal utility gained from consumption of 
health services (relative to other goods) is expected to be greater than that for the 
“average” individual. As a result, individuals with PD are expected to consume more 
healthcare services in order to maximize their utility. Services such as neurologist visits, 
physical/occupational therapy, and speech therapy help these individuals improve their 
health stock (or, more accurately, help delay/reduce their loss in health stock) and thus 
allow them to gain more utility from leisure and other consumption goods, as well as to 
survive longer (35–43). 
Selection of a medical home provider 
The decision to consume health care is not as simple as choosing to receive health 
care. In addition to choosing to receive any care, the individual must also decide – given 
that they need care – from which provider to receive their care. The theory behind the 
patient’s choice of provider may be represented by the random utility model as 
described by McFadden (44).  In this model, the patient chooses their health care 
provider to maximize their utility. In its simplest format, the random utility model can be 
written as follows: 
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Uni = βXn + δZi + εni 
Where n represents the individual (for a set of N individuals), i represents the provider 
option (from a set of I available providers), Xn represents a vector of covariates specific 
to individual n and Zi represents a vector of covariates provider option i, and εni 
represents a random error component. Everyone then chooses the provider that 
maximizes their utility function. 
Several components of Pi are relevant to the patient’s choice of provider. These 
may theoretically include “convenience,” cost to the patient, and - most importantly for 
the purposes of this study - the quality of the provider.  Convenience measures may 
include: 
- Location: the proximity of the provider to the patient will affect the travel time 
necessary to get to and from the provider. A reduction in travel time leads to an 
increase in utility, ceteris paribus, by reducing the opportunity cost associated 
with a visit;  
- Waiting time: like the value of location, the anticipated waiting time once the 
patient arrives at the provider directly affects patient utility;   
- Hours of availability: patients gain utility from expanded hours of availability by 
having greater choice in terms of scheduling visits at an optimal time. 
Additionally, having added hours reduces the risks of delay in receiving care 
when care is needed. 
The impact of cost on utility is straightforward, as individuals gain utility from money 
through the ability to consume more goods. However, I assume that insurance (in this 
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case Medicare) provides similar coverage for all in-network providers such that all in-
network providers provide care at the same medical cost. This assumption ignores any 
costs associated with convenience factors (such as travel costs as noted above). As 
such, I assume that the impact of cost on the patient’s choice is to simply limit the 
individual’s choice set to those providers within the health plan’s network. The individual 
will immediately rule out all out-of-network providers regardless of quality or 
convenience.  Furthermore, I exclude those dually eligible for Medicaid, which aids in 
relieving budget constraints that may restrict individuals’ choice of receiving any 
outpatient preventive care. Thus, once the choice set has excluded out-of-network 
providers, I assume that a provider’s fee schedule has no exogenous effect on the 
individual’s selection of provider. 
Finally, quality plays a part in the patient’s choice.  In theory, the quality of the 
provider should provide the most substantial direct impact on the production function 
outlined by Grossman. Quality of care directly relates to an individual’s human capital.  
Higher-quality care should lead to better health outcomes, which in turn leads to 
increases in human capital.  By comparison, the other contributing factors (time, 
access) have only more transient and indirect effects on one’s health. However, 
individuals are usually insufficiently informed to make an educated choice based on 
quality. As such, the measure that contributes to the patient’s utility may be more simply 
thought of as the perceived quality of the provider (45). Perceived quality can be derived 
from things such as the cleanliness of the facility, the provider’s ratings (e.g., Medicare 
star rating), or broader concepts of a provider’s reputation.  
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The quality signal provided by a provider’s NCQA medical home rating (for 
example) may thus be a determining factor swaying the patient’s choice of provider.  In 
the case of a medical home, the patient-centered focus, continuity of care, and 
increased access to services represent factors that may increase the perceived quality 
to the individual seeking a healthcare provider. Unobserved characteristics of either the 
provider or the Medicare beneficiary may also affect the choice of the provider by the 
patient.  
Effect of medical homes on outcomes 
With respect to the effect of PCMH on outpatient resource use, outcomes, and 
costs, I assume that an individual’s healthcare resource use can be defined as follows: 
Yni = α0 + α1Xn + α2Qi + υni 
Where Yni represents the outcome for individual n receiving care from provider i, Xi 
represents a vector of patient characteristics specific to patient n (such as age, sex, 
race, and patient health), and Qi represents a vector of quality characteristics specific to 
provider i. We can then think of Qi as a function of PCMH recognition, where E(Y|QPCMH) 
> E(Y|QOther). The underlying framework through which medical homes improve quality 
of care and thus health outcomes and costs for Medicare beneficiaries with PD is as 
follows: 
- Patient-centered focus: the medical home’s patient-centered focus and emphasis 
on patient education should lead to a better understanding in the patient of the 
importance of adherence, a better understanding of how/when to take their 
medication, and perhaps help in developing strategies to improve medication 
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adherence. These potential benefits of care should lead to fewer complications 
and expensive hospitalizations due to a patient’s failure to follow the medical 
plan. Additionally, the focus on patient education may help emphasize the 
importance of receipt of preventative outpatient services such as neurologist 
visits, physical/occupational therapy, and speech therapy; 
- Coordinated care: the coordinated care led by a primary care physician in which 
various care providers interact with the primary care physician and patient should 
lead to better management of complex patients with PD. In the case of patients 
with PD and depression, the medical homes model should provide better 
continuity of care coordination between the primary care physician and the 
psychiatrist, leading to better health outcomes and reduced costs. The 
coordination of care should also reduce the probability of a patient receiving 
contraindicated medications, which is not uncommon in the treatment of PD (46); 
- Access to care: the PCMH model is designed to improve patient access to care, 
via telemedicine, expanded office hours, and other strategies. As such, we 
should see an increase in primary preventive care and a reduction in more costly 
resource use such as ED visits and hospitalizations. 
Based on these three key areas of improved quality of care, I hypothesize that we 
will see an increase in utilization of outpatient health care (e.g., neurologist visits; 
physical/occupational therapy; speech therapy; psychotherapy) and a reduction in 
adverse outcomes such as hospitalizations (falls, aspiration pneumonia, etc.). This is 
due to a combination of improved access to care as well as improved quality of care 
provided during each outpatient visit (better coordination of care and patient-centered 
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focus both contribute to this). It is unclear whether the quality improvements associated 
with PCMH participation will lead to an increase in costs (due to more outpatient 
resource use) or a decrease (due to the potential avoidance of expensive 
hospitalizations). But I would anticipate that increases in less-costly outpatient 
preventive services will be at least offset by proportionate decreases in risk of high-cost 
hospitalizations. Thus, in addition to health outcomes and outpatient resource utilization, 




CHAPTER 3: EFFECT OF MEDICAL HOMES ON PARKINSON’S DISEASE CARE 
Overview 
Objective: To estimate the effect of patient-centered medical homes (PCMH) on 
quality of care, health outcomes, and costs in Medicare beneficiaries with Parkinson’s 
disease (PD). 
Methods: A retrospective medical claims database analysis of Medicare 
beneficiaries with PD from 2007 to 2013. Generalized estimating equations were used 
to estimate the effect of beneficiary PCMH participation on quality of care (neurologist 
visit, physical therapy, and speech therapy), clinical outcomes (hospitalizations for falls, 
aspiration pneumonia, and pneumonia/aspiration pneumonia), and total Medicare costs, 
controlling for demographic characteristics and disease severity. Selection bias was 
addressed using an instrumental variables technique. 
Results: After controlling for selection bias and clustering, patients who participated 
in a PCMH were more likely to visit a neurologist (79.1% vs 68.5%; p<0.05) and a 
physical therapist (3.3% vs 1.9%; p<0.05) annually. Conversely, fewer individuals in 
PCMH incurred annual hospitalizations for falls (3.4% vs 4.4%; p<0.05) and 
pneumonia/aspiration pneumonia (4.9% vs 6.3%; p<0.01). No significant relationship 
was observed between PCMH participation and aspiration pneumonia or Medicare 
costs. 
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Conclusions: PCMH-treated Medicare beneficiaries with PD received better quality 
of care are expected to incur fewer negative health outcomes at no additional costs, 




Introduction and Background 
Parkinson’s disease (PD) is a chronic, progressive neurological disorder affecting 
nearly 1 million people in the US; nearly 500,000 patients over the age of 65 have PD 
(1). As with many chronic, progressive diseases, individuals with PD are more likely to 
require physician visits, emergency department (ED) visits, home health care, and long-
term care than those without PD (2).  Outpatient visits to neurologists, physical 
therapists, occupational therapists, and speech therapists have been associated with 
better outcomes in PD (35–43,47,48). Because of its complex nature, care for patients 
with PD requires an integrated, interdisciplinary patient-centered team of providers 
collaborating jointly with the patient to develop the optimal care plan (10,31–33). PD 
patients also require personalized care patterns in response to the progression of the 
disease (10).  
The patient-centered medical home (PCMH) has the potential to provide such care.  
According to the Agency for Healthcare Research and Quality (AHRQ), the PCMH has 
five attributes (15): (i) Comprehensive care provided through a team of care providers 
including physicians, nurses, pharmacists, nutritionists, social workers, and educators; 
(ii) Patient-centered focus built on relationship-based, holistic care of the patient; (iii) 
Coordinated care in which a strong level of communication is fostered between the 
patient, family, and care providers; (iv) Better access to services, including greater 
hours, anytime support via telephone or electronic access, shorter waiting times; and (v) 
Improved quality and safety.  Several previous studies have estimated the potential 
benefit of PCMH on healthcare costs and outcomes. Flottemesch and colleagues (24) 
found that the benefit of PCMHs may be limited to complex patients. Christensen and 
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colleagues (25) found that the Walter Reed PCMH reduced costs in patients with and 
without chronic conditions, but the relative cost-savings were greater in patients with 
chronic conditions. More recent research has also shown PCMHs may be particularly 
beneficial for those with complex medical conditions (26–30). These results suggest that 
the PCMH model appears to provide the greatest value of to those individuals with 
complex medical conditions. 
While research into care for PD is extensive and evidence for the effectiveness of 
PCMH is expanding, a review of the literature found no studies estimating the impact of 
PMCH on healthcare for individuals with PD. Thus, the objective of this study is to 
estimate the effect of patient-centered medical homes (PCMH) on quality of care, health 
outcomes, and Medicare costs among Medicare beneficiaries with Parkinson’s disease. 
Methods 
IRB approval statement: this study was approved by the Institutional Review Board at 
the University of North Carolina at Chapel Hill. 
Dataset and study population 
The analyses utilized medical claims data from a nationally representative, 
longitudinal, 20 percent sample of fee-for-service Medicare beneficiaries aged 65+ 
enrolled in Medicare Parts A, B, and D at any point between 2007-2013. These years of 
data were selected because the National Committee on Quality Assurance (NCQA) 
began its widely-adopted medical home recognition program in 2008 (19). As such, the 
years sampled comprise a time period preceding and following the introduction of the 
NCQA program. The dataset contains patient-level data on demographic characteristics 
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and extensive detail on medical insurance claims for each patient. Within the dataset, 
we identified PD beneficiaries (ICD-9 code 332.0) with any Part A or Part B claims 
during a year. Furthermore, given the nature of the condition, we excluded any 
beneficiaries without a Part D claim during each study year, as we assume all PD 
patients will be treated with pharmacotherapy. All data were analyzed at the person-
year level.  
PCMH participation and instrumental variable 
The key explanatory variable was participation in a PCMH. To estimate the effect of 
PCMH on outcomes, we merged NCQA provider recognition data with Medicare claims 
using the provider national provider index, Though the NCQA definition considers many 
factors in generating a recognition score (19), we had limited information on how the 
scores for each provider were derived. Given the limited information available, we 
considered PCMH recognition to equal one if an individual provider received any level of 
PCMH recognition during the year and zero otherwise. 
Enrollees were attributed to PCMH participation if they had any claim with a PCMH 
provider during the year. This approach was chosen due to the complex nature of PD 
and the various healthcare visits required to treat the disease. PD patients are likely to 
see a variety of healthcare providers within a year given the complexity of the disease, 
and unlike healthier beneficiaries they may not see their primary care physician most 
frequently. 
A patient’s choice of provider likely depends upon multiple characteristics 
associated with both the patient and outcomes of interest. That is, some of the factors 
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that might predict better outcomes may also predict whether the patient seeks out 
PCMH care. As such, we used an instrumental variable approach to address this 
endogenous provider selection. Specifically, we used the number of PCMH providers 
per 100,000 Medicare beneficiaries in the hospital service area as an instrument to 
predict PCMH participation. We estimated the number of Medicare beneficiaries per 
hospital service area using the Dartmouth Atlas of Health Care (49). We then merged 
the number of PCMH providers in each hospital service area based on ZIP code. The 
key assumption with instrumental variables that the instrument is correlated with the 
likelihood of a beneficiary selecting in a PCMH but is not otherwise correlated with the 
outcomes of interest.  
Outcomes of interest 
The outcomes of interest included the annual probability of having a visit to a 
neurologist, physical/occupational therapist, speech therapists. These are measures 
that the American Academy of Neurology (AAN) views as high-quality care and have 
been shown to improve outcomes in PD (35–43,47,48,50,51). We hypothesize that 
PCMH participation will lead to a higher probability of receipt of these forms of care. We 
were also interested in health outcome measures, including the probability of 
hospitalization for falls and aspiration pneumonia, two common problems experienced 
by PD patients (52–58). Because aspiration pneumonia may be underreported in a 
hospital setting (59), we also considered a pneumonia variable including both aspiration 
pneumonia and all-cause pneumonia. We hypothesize that PCMH participation will 
reduce the probability of these hospitalizations due to expected improvements in the 
quality of care (e.g., better care coordination and expected increases in use of higher-
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quality care services). Finally, to assess the value of PCMH participation to Medicare, 
we also considered total costs to Medicare (based on the sum of all Medicare 
reimbursements per enrollee annually). We hypothesize that PCMH participation will 
result in either no increase in spending or a significant decrease in spending along with 
the improved clinical outcomes. Variable definitions for each outcome can be found in 
Table 1. 
Control variables 
To account for confounding factors, we controlled for demographic characteristics 
(age in years, race/ethnicity, and sex). Because claims data has limited information to 
accurately assess the severity of PD, we included a series of measures to approximate 
disease severity, including claims for durable medical equipment (DME) ambulatory 
devices, maximum daily levodopa dose (mg/day), and claims for cholinesterase 
inhibitors for cognitive impairment. We also included a measure of depression as well 
as comorbid conditions using the Charlson comorbidity index (CCI) to control for other 
conditions that may influence both PCMH participation and health outcomes (60,61). 
Variable definitions can be found in Table 1. Finally, to account for the longitudinal data 
sample and control for any effects of time on outcomes, we included covariates for the 
year of each person-year observation. Specifically, we included a quadratic function of 




Generalized estimating equations (GEE) regression techniques were used to 
estimate the effect of PCMHs on outcomes to account for repeated observations on 
patients across years and the clustering within patients (62). Because all the outcomes 
are binary variables, we assumed a binomial distribution and logit link function. For the 
correlation structure, we used the quasi-likelihood under the independence model 
criterion (QIC) to determine the best fit (63). Specifically, we considered independent, 
exchangeable, and unstructured correlation structures. While the independent structure 
had the lowest QIC, the exchangeable structure had a more plausible set of 
assumptions and comparably low QIC (within 0.2%, see Table 2). As such, all analyses 
were run assuming an exchangeable correlation structure. 
Because selection into a PCMH is likely to be endogenous, we used a two-stage 
residual inclusion (2SRI) IV approach (64,65). The approach has been shown to be a 
valid approach to controlling for endogeneity when estimating average treatment effects 
(64,66). In this approach, a two-step regression is applied. The first stage of the 2SRI 
regression predicts PCMH participation given the estimates for the instrument as well as 
the covariates to be included in the second stage regression. The second stage 
regression predicts the outcomes of interest given the covariates’ estimates as well as 
the residuals (error terms) from the first stage. 
To account for the inclusion of first-stage residuals in the second stage equation 
and the impact on standard errors, we used bootstrapping (1,000 replicates) clustered 
at the beneficiary level to estimate the standard errors. Because the outcomes of the 
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models are in log odds, the marginal effects will differ for everyone. As such, we 
generated the average marginal effects from the bootstrapped results. 
Results 
Demographic characteristics 
The analysis included 103,336 Medicare beneficiaries with PD who contributed 
238,722 person-years from 2007 to 2013 (Table 3). The sample was comprised of 
52.2% male, 94.5% were white/Caucasian, 2.8% Black, and 0.7% Hispanic. The 
average age of the study population was 79.3 years.  
PCMH participation was estimated to be 13,962 person-years, or 5.8% of the 
sample, with average number of PCMH provider visits during the entire study period of 
7.31 (SD=8.85) visits, with 9,788 beneficiaries (77.4%) having more than one visit to a 
single PCMH provider. In a naïve test of significant differences, enrollees who 
participated in PCMH were significantly (p<0.01) more likely to utilize most healthcare 
services and have higher Medicare costs. PCMH participants were significantly more 
likely to have depression and comorbidities. We observed highly-significant (p<0.0001) 
differences in CCI and depression. No significant differences were observed in the 
percentage of enrollees who were white, who took medication for cognitive impairment, 
or who took levodopa.  
First-stage Results 
The results of the first-stage regression suggested that availability of PCMH 
physicians is a strong instrument. A Wald test of significance found that number of 
PCMH providers per 1,000 Medicare enrollees in the hospital service area strongly 
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predicted PCMH participation (χ2 = 7424.25; p<0.0001), indicating that the number of 
PCMH providers per 1,000 enrollees may be a strong instrument if it is not otherwise 
correlated with the outcome of interest (67). Because we had only one instrument, we 
could not conduct a test for overidentification (68). Other factors also had significant 
effects on the likelihood of PMCH participation: CCI positively predicted PMCH 
participation, as did several of the PD severity indicators. First-stage regression 
coefficients can be seen in Table 4. 
Outpatient care results 
Average marginal effects of PCMH participation can be seen in Table 5. We found 
that enrollees participating in a PCMH were significantly more likely to see a neurologist 
and receive physical therapy or speech therapy (p<0.001). The average marginal effect 
of PCMH participation on physical therapy was 0.127 (SE=0.011), meaning that PCMH 
participation increased the probability of seeing a neurologist by 12.7 percentage points. 
For a Medicare enrollee with PD with the mean/modal characteristics, this would 
translate to an increase in probability from 66.2% to 78.9%. Similarly, PCMH 
participation was estimated to yield a 9.6 percentage point increase in the likelihood of 
receiving physical therapy and a 2.8 percentage point increase in probability of 
receiving speech therapy (Table 5). 
Several of the covariates were significantly associated with the outcomes of interest 
as well. Age was negatively associated with receipt of these services (p<0.001). Blacks 
(p<0.001) and Hispanics were significantly less likely to receive outpatient services than 
Whites. Maximum daily levodopa dose, as a marker for severity of PD, was significantly 
(p<0.001) associated with a higher likelihood of receipt of neurologist care, physical 
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therapy, and speech therapy. Use of cholinesterase inhibitors, claims for DME, and CCI 
score were all associated with a higher likelihood of receiving care as well, to varying 
degrees.  
Hospitalization results 
PMCH participation was estimated to significantly reduce the probability of 
experiencing a hospitalization for falls (p<0.05) and of experiencing a hospitalization for 
pneumonia or aspiration pneumonia (p<0.01) (Table 5). The average marginal effect of 
PMCH participation on these outcomes was a 1.5 percentage point decrease in the 
likelihood of experiencing a hospitalized fall and a 2.5 percentage point decrease in the 
likelihood of experiencing a hospitalization for pneumonia or aspiration pneumonia 
(Table 5). PCMH participation was not associated with the likelihood of hospitalized 
aspiration pneumonia. 
As with the outpatient outcomes, several covariates had significant relationships 
with the outcomes of interest as well. Age was associated with a higher risk of each 
type of hospitalization (p<0.001). Minorities were significantly less likely to be 
hospitalized for falls than Whites (p<0.001). Levodopa dose was associated (p<0.001) a 
lower likelihood of hospitalization. Use of drugs to treat cognitive impairment, claims for 
DME, and CCI score were all associated with a higher likelihood of all types of 
hospitalizations considered (p<0.001). 
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Medicare cost results 
After controlling for selection bias and other confounding factors, we observed no 
significant relationship (p=0.506) between PMCH participation and Medicare costs 
among Medicare beneficiaries with PD (Table 5). 
Discussion 
To our knowledge, we conducted the first study to estimate the impact of PCMH 
participation on receipt of outpatient care, risk of PD-related hospitalizations, and total 
Medicare costs among Medicare beneficiaries with PD. We found that participation in a 
PCMH increases the likelihood of seeing a neurologist and receiving 
physical/occupational and speech therapy. The absolute increase in utilization of these 
services may be small, but the relative change is dramatic. We find a 19 percent relative 
increase in neurologist use, a 75 percent increase in physical/occupational therapy use, 
and a 93 percent increase in speech therapy use. PCMH participation also reduced the 
risk of hospitalizations for falls and for pneumonia among Medicare enrollees with PD, 
with each reduction representing an approximate 25 percent reduction. Though there 
was a reduction in risk of aspiration pneumonia, the difference was not significant. No 
significant differences in Medicare costs were observed. 
Our findings suggest that PCMH participation improves care for beneficiaries with 
PD. Increased use of neurologist care, physical therapy, and speech therapy may be 
thought of as direct effects of the PCMH program: improving the process of care for 
patients with complex conditions. Our results were less conclusive for PCMH effect on 
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hospital outcomes. Use of neurologists and receipt of physical therapy and speech 
therapy have been shown previously to be associated with improved outcomes (47).  
The PCMH group had significantly higher CCI score and significantly higher 
proportion of individuals with depression than the non-PCMH group. This suggests that 
some selection into PCMH is occurring, as patients with more severe health concerns 
appear to be selecting to participate in PCMH.  The 2SRI approach was thus critical in 
controlling for selection bias, as we found that PCMH care led to significant 
improvements in most outcomes of interest.  
We found that PCMH care did not lead to significantly different costs to Medicare. 
Thus, PCMH care may provide a cost-effective mode of primary care for Medicare 
beneficiaries with Parkinson’s disease. Given the inconsistent evidence of success of 
pay for performance approaches to improve quality of care (69), it is especially 
interesting that the PCMH model may provide an approach to improving quality of care 
without leading to an increase in cost to Medicare. 
As with any retrospective secondary data analysis, this study is subject to 
limitations. First, IV regression provides the effect of PCMH participation on those who 
participate in treatment. In this case, that means those whose decision to participate in 
a PCMH program is contingent upon the number of PCMH providers in the local area. 
We cannot assess the effect of PCMH on those who would always participate in a 
PCMH, nor on those who would never participate.   
A second limitation of this study is that we lacked data on potentially important 
control variables, such as PD severity. Ideally, we would include a validated measure 
(70–73).  However, we included several control variables that may provide a proxy 
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associated for disease severity. We also lacked data on caregivers for the PD 
beneficiaries. However, the IV approach should control for this potential threat, as it is 
unlikely there is a correlation between availability of caregivers or PD severity and 
availability of PCMH providers.  
Third, we relied on the NCQA definition of PCMH, though there are other definitions. 
It is possible that a provider could be of comparable quality to NCQA-recognized 
provider but simply not recognized by NCQA. If so, this would underestimate the benefit 
of PMCH participation. If we could expand the definition of PCMH participation to 
include all models of PCMH recognition, we would likely capture more higher-quality 
providers within the PCMH group. Fourth, these results may only be generalizable to 
Medicare beneficiaries.  
Finally, while we considered 7 years of claims data and the average number of 
visits (7.31) to a PCMH provider suggest that we are indeed capturing some of the 
longitudinal effects of PCMH care, the average years per enrollee in the dataset was 
just over two years. PD is a long-term disease, and some health outcomes may take 
more than 10 years to manifest (74,75). As such, we may not have enough longitudinal 
information per enrollee to quantify the longer-term health impact of PCMH participation 
on PD care. Furthermore, as just over 20 percent of PCMH participants had only a 
single visit to a PCMH provider, the effects of PCMH participation seen in this study 
may be underestimated. These questions could be explored further as additional years 
of data become available, or in a patient population for which each enrollee’s 
contribution to the sample includes more years of data. 
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This study contributes to the knowledge about care for PD patients. Our findings 
suggest that PCMH may provide benefit to Medicare beneficiaries with PD. Specifically, 
participation in PCMH significantly increased the likelihood of receiving outpatient visits 
with a neurologist, as well as receiving beneficial services such as physical/occupational 
therapy and speech therapy. These findings are consistent with the theoretical value of 
PCMH care, in that a coordinated, multidisciplinary, patient-focused model of care may 
lead to improved outcomes for patients with PD. Finally, the improvements in quality of 
care and health outcomes at no significant difference in costs suggest that PCMH care 
may be a cost-effective mode of primary care for Medicare beneficiaries with PD. 
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Tables 
Table 1. Codes used to define clinical covariates 
Parameter P 
Outcomes  




HCPCS code 97001, 97002, 97003, 97004, 97012, 97016, 
97032, 97110, 97112, 97113, 97116, 97124, 97140, 97150, 
97530, 97537, 97760, or 97761 
Speech therapy HCPCS code 92506, 92507, 92508, or 92526 
Hospitalized falls ICD-9 code E880-E885, E888 
Hospitalized aspiration 
pneumonia 





ICD-9 code 486.0 or 507.0 
Covariates  
Cholinesterase inhibitors Part D claims for donepezil, galantamine, memantine, 
rivastigmine 
Depression At least on IP, SNF, HHA, HOP or Carrier claim with 
diagnosis codes during the 1-yr period, ICD-9 code 296.20, 
296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 
296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.51, 
296.52, 296.53, 296.54, 296.55, 296.56, 296.60, 296.61, 
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296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 
300.4, 309.1, 311 
DME for ambulatory 
assistance 
E0100-E109, E0130-0139, E0160-E0179, E0250-E0379, 
E0950-E1299 
Dopamine agonists Part D claims for apomorphine, bromocriptine, cabergoline, 
ciladopa, dihydrexidine, dinapsoline, doxanthrine, 
epicriptine, lisuride, pergolide, piribedil, pramipexole, 
porphylnorapomorphine, quinagolide, ropinirole, rotigotine, 
or sumanirole 
DME = durable medical equipment; HCPCS = Healthcare Common Procedure Coding System; HHA = 
home health agency; HOP = hospice; ICD-9 = International Classification of Disease, 9th Revision; IP = 
inpatient; SNF = skilled nursing facility. 
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Table 2. Results of the quasi-likelihood under the independence model criterion 
test 
Correlation Structure Independent Exchangeable Unstructured 
First stage model (PCMH 
participation) 
81,489.732 81,551.340 81,790.388 
Second stage models:    
Neurologist visit 281,622.273 282,843.428 283,549.140 
Physical therapy 181,360.260 181,480.340 181,446.832 
Speech therapy 62,990.206 62,995.799 62,995.209 
Hospitalized falls 96,818.061 96,820.006 96,820.058 
Hospitalized aspiration pneumonia 66,423.437 66,437.754 66,434.369 
Hospitalized pneumonia/aspiration 
pneumonia 
130,067.931 130,109.584 130,102.912 
Medicare costs 5,090,169.052 5,090,523.751 5,090,471.295 
Values presented are the QIC values for each regression model. The “first stage” row refers to the first-
stage regression predicting PCMH use. The remaining 7 rows represent the various second-stage 
regressions for each outcome of interest. 
PCMH = patient-centered medical home; QIC = quasi-likelihood under the independence model criterion. 
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Dependent variables     
Neurologist use (%) 66.2% 74.3% 65.7% p<0.0001 
Physical therapy (%) 12.9% 15.7% 12.8% p=0.0002 
Speech therapy (%) 3.0% 4.1% 2.9% p=0.0052 
Hospitalized fall (%) 6.5% 7.6% 6.5% p<0.0001 
Hospitalized aspiration 
pneumonia (%) 




9.2% 10.7% 9.1% p<0.0001 









Key explanatory variable/IV     
PCMH participation (%) 5.8% 100.0% 0.0% N/A 
PCMH physicians per 
1,000: mean (SD) 
0.35 (0.88) 1.73 (1.68) 0.27 (0.73) p<0.0001 
Control variables     
Age (years): mean (SD) 79.3 (7.4) 79.1 (7.5) 79.3 (7.4) p=0.0017 
Male (%) 52.2% 53.4% 52.1% p=0.0026 
Race (%)     
White/Caucasian 94.6% 94.6% 94.6% p=0.6416 
Black 2.7% 3.1% 2.7% p=0.0239 
Hispanic 0.6% 0.4% 0.6% p<0.0001 
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Asian 0.7% 0.5% 0.7% p=0.0021 
Native American/Pacific 
Islander 
0.2% 0.0% 0.2% p<0.0001 
Other 1.0% 1.1% 1.0% p=0.4457 
Maximum levodopa dose: 
mg/day (SD) 
281.0 (254.5) 261.5 (225.8) 282.2 (256.1) p=0.4094 
Dopamine agonist use (%) 12.6% 11.8%  12.7% p=0.2703 
Cholinesterase inhibitor use 
(%) 
22.3% 22.0% 22.3% p=0.0050 
DME claims (%) 13.1% 14.1% 13.0% p=0.0003 
Depression (%) 29.3% 36.5% 28.8% p<0.0001 
Charlson comorbidity index: 
mean (SD) 
1.99 (2.01) 2.24 (2.15) 1.97 (2.00) p<0.0001 
Year: %     
2007 (year=0) 12.2% 0% 13.0% p<0.0001 
2008 12.8% 2.0% 13.6% p<0.0001 
2009 12.9% 2.4% 13.8% p<0.0001 
2010 13.5% 8.2% 14.1% p<0.0001 
2011 14.3% 16.6% 14.2% p<0.0001 
2012 15.6% 28.4% 14.7% p<0.0001 
2013 18.6% 44.1% 17.0% p<0.0001 
DME = durable medical equipment; Mg = milligram; PCMH = patient-centered medical home; SD = 
standard deviation. 
Data are presented at the person-year level. 
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Table 4. First-stage regression coefficients predicting PCMH participation 
Parameter Coefficient Standard Error P-Value 
PCMH physicians per 100,000 
beneficiaries 
0.6216 0.0072 p<0.001 
Age (years) -0.0049 0.0015 p=0.001 
Male -0.0459 0.0221 p=0.038 
Race    
Black -0.1004 0.0627 p=0.110 
Hispanic -0.6142 0.1774 p=0.001 
Asian -0.5511 0.1551 p<0.001 
Native -1.499 0.5705 p=0.009 
Other -0.2326 0.1085 p=0.032 
Maximum daily levodopa dose 0.0001 0.0000 p=0.068 
Dopamine agonist use 0.0165 0.0307 p=0.592 
Cholinesterase inhibitor use -0.0221 0.0241 p=0.360 
Ambulatory devices 0.1649 0.0270 p<0.001 
Depression 0.2247 0.0206 p<0.001 
Charlson comorbidity index 0.0647 0.0045 p<0.001 
Year 1.638 0.0450 p<0.001 
Year squared -0.1448 0.0050 p<0.001 
PCMH = patient-centered medical home.  
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Outpatient results      
Neurologist visit 0.659 0.064 0.127 0.011 p<0.001 
Physical therapy 0.706 0.079 0.096 0.012 p<0.001 
Speech therapy 0.725 0.136 0.028 0.006 p<0.001 
Hospitalization results      
Falls -0.286 0.119 -0.015 0.006 p=0.010 
Aspiration pneumonia -0.006 0.130 -0.0002 0.004 p=0.960 
Pneumonia/aspiration 
pneumonia 
-0.330 0.091 -0.025 0.008 p=0.001 
Medicare costs 0.0236 0.035 524.83 789.31 p=0.506 
Coefficients are the beta coefficients from the second-stage regression. Average marginal effect is the 
estimated marginal effect of PCMH participation. For outpatient results, the marginal effects represent a 
percentage-point change in the likelihood of receipt of the outpatient service. Hospitalized measures are 
continuous variables, and as such the marginal effect represents the change in number of hospitalizations 
per year associated with PCMH participation. Standard errors and significance level were estimated using 





CHAPTER 4: EFFECT OF MEDICAL HOMES ON PARKINSON’S DEPRESSION 
Overview 
Objective: To estimate the effect of patient-centered medical homes (PCMH) on 
quality of depression care, health outcomes, and Medicare costs among Medicare 
beneficiaries with Parkinson’s disease (PD) and depression. 
Methods: A retrospective medical claims database analysis of Medicare 
beneficiaries with PD from 2007 to 2013. Multivariate generalized estimating equations 
were used to estimate the effect of PCMH participation on a quality of care (outpatient 
psychotherapy visits; avoidance of contraindicated, dopamine-blocking drugs; 
antidepressant use), health outcomes (hospitalizations for depression; hospitalization 
for suicidal behavior), and Medicare costs, controlling for demographic characteristics 
and disease severity. To control for potential bias due to adverse selection into PCMH 
care, we used two-stage residual inclusion. 
Results: Patients in PCMHs experienced a 5.9 percentage-point increase in the 
probability of receiving psychotherapy (p<0.05) and a 7.3 percentage point reduction in 
risk of receiving dopamine-blocking agents (p<0.001) annually compared with 
beneficiaries not participating in a PCMH. PCMH participation did not have a significant 
effect on the probability of antidepressant use, annual depressive hospitalizations, 
hospitalizations due to suicidal behavior, or Medicare costs. 
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Conclusions: PCMH-treated Medicare beneficiaries with PD and depression 
received better quality of care. Not observing significantly differences in health 
outcomes or Medicare costs may be due to the limited longitudinal data available per 
enrollee (<2 years). Still, the significant increase in psychotherapy use and reduction in 
contraindicated medications at no additional cost to Medicare suggests that PCMH care 
may be a cost-effective approach to improving the quality of depression care and 
managing the complex characteristics of PD patients with depression. 
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Introduction and Background 
Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
affecting nearly 500,000 people over the age of 65 in the United States (1). Though 
motor systems such as tremors, bradykinesia, and rigidity are the most well-known 
characteristics of PD, the disease has several non-motor symptoms including sleep 
disorders, fatigue, constipation, sensory dysfunction, cognitive deficits, anxiety, and 
depression (5). Given its complex nature, care for PD requires an integrated, 
multidisciplinary team of providers collaborating to provide patient-centered care 
(10,31–33).  
Of the many non-motor symptoms of PD, depression is highly prevalent (76–78). 
The presence of depression among individuals with PD is associated with a greater risk 
of poor motor function (79), longer hospital length of stays (80), more healthcare 
resource utilization (81), reduced ability to care for one’s self (82) (Bugalho, et al., 
2016), more comorbidities (76,81), and lower health-related quality of life (83,84). 
Antidepressants and psychotherapy approaches have each been found to improve 
depressive symptoms in individuals with comorbid depression and PD (85,86). 
However, like depression in the general population, individuals with PD are 
undertreated for their comorbid depression (78,87). As such, improved depression 
management is important to consider in the healthcare plan of individuals with PD. 
The patient-centered medical home (PCMH) is a model of healthcare that has been 
broadly defined by the following attributes: (i) Comprehensive care provided through a 
team of care providers including physicians, nurses, pharmacists, nutritionists, social 
workers, and educators; (ii) Patient-centered focus built on relationship-based, holistic 
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care of the patient; (iii) Coordinated care in which a strong level of communication is 
fostered between the patient, family, and care providers; (iv) Better access to services, 
including greater hours, 24-hour support via telephone or electronic access, shorter 
waiting times; and (v) Improved quality and safety (15). Though there are many models 
of PCMH, the model formalized in 2008 by the National Committee for Quality 
Assurance (NCQA) is the most widely adopted by practices seeking PCMH recognition 
(19). The PCMH model may be an effective approach for the health care management 
of individuals with complex conditions such as PD and comorbid depression. 
Previous studies have found that PCMH may provide benefits in caring for patients 
with complex conditions (24,25) including those with depression (26–30). Given the 
complex nature of PD and comorbid depression, participation in a PCMH may result in 
improved care for these patients. In a previous study, we found a highly significant 
effect of PCMH on outpatient utilization among Medicare beneficiaries with PD, 
suggesting potential quality improvements associated with PCMH care (Aim 1). While 
research into care for PD and depression is extensive and studies of the value of PCMH 
care are becoming more available, to our knowledge no studies have estimated the 
impact of PMCH on outcomes for individuals with PD and comorbid depression. As 
such, our objective is to estimate the effect of the PCMH on quality of depression care, 





Dataset and study population 
The study population consisted of fee-for-service Medicare enrollees diagnosed 
with depression and PD from 2007 to 2013; this period aligns with the introduction of 
NCQA medical home recognition in 2008. Claims data for these individuals were 
obtained from a nationally representative, longitudinal, 20 percent sample of Medicare 
beneficiaries aged 65 years and older enrolled in in Medicare Parts A, B, and D at any 
point during the time period. PD beneficiaries were identified based on a Part A or Part 
B claim with ICD-9 code 332.0 and a depression diagnosis as identified based on a 
previously-outlined algorithm for major depression (88) (see Table 6 for details). Patient-
level demographic characteristics and insurance claims for procedures, services, 
medications, and devices were collected for each patient. Exclusion criteria included 
those dually eligible for Medicaid at any month of the year to better capture all claims 
information, and those beneficiaries without a Part D claim during the year. All estimates 
are at the person-year level. 
Outcomes of interest 
The outcomes of interest included quality of depression care (direct effect of PMCH 
participation), health outcomes (indirect effect of PCMH participation), and Medicare 
costs. Quality of depression care included: receipt of psychotherapy; contraindicated 
medication use (5); and medication adherence, all of which have been shown to 
improve outcomes (85,86,89,90) and are recommended by practice guidelines (91,92). 
We hypothesize that PCMH participation will lead to a higher probability of receipt of 
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psychotherapy, a lower likelihood of using contraindicated medications, and a higher 
level of medication adherence. The health outcomes included hospitalization for 
depression and hospitalization for suicidal behavior. We hypothesize that higher quality 
of depression care would lead to fewer of the hospitalizations. Finally, to assess the 
value of PCMH participation to Medicare, we also considered total Medicare 
expenditures per beneficiary per year. Variable definitions for all outcomes of interest 
are outlined in Table 6. 
Key explanatory variable 
Beneficiaries’ participation in a PCMH was our explanatory variable of interest. 
Given the complex nature of PD with comorbid depression, we anticipated that 
individuals would see multiple providers throughout the year. As a result, noting that 
claims data do not provide a primary care provider distinction, identifying a singular 
primary care provider is challenging. Thus, we attributed beneficiaries to PCMH 
participation if we observed any outpatient claim with a PCMH provider during the year.  
While we are interested in estimating the effect of PMCH participation on outcomes, 
we anticipate that selection of primary care provider is endogenous, i.e., correlated with 
both the outcomes and other confounding factors. If ignored, this endogeneity could 
bias our regression results. To account for endogeneity of a beneficiary’s provider 
selection, we used an instrumental variable (IV) approach. The instrument used to 
predict PCMH participation was the number of PCMH providers available per 100,000 
Medicare beneficiaries within the beneficiary’s hospital service area; this was measured 
using Medicare population per hospital service area data from the Dartmouth Atlas of 
Health Care data mapped to beneficiary zip code (49). The key assumption for the 
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instrument is that PCMH participation would be correlated with the availability of PCMH 
providers, but availability of PCMH providers in the local area would not likely be 
otherwise correlated with a patient’s health outcomes. 
Control variables 
To control for potential confounding, we included several additional control variables 
likely to be correlated with healthcare resource use and potentially correlated with 
selection into PCMH care. Control variables included demographic characteristics such 
as age (in years), race/ethnicity, and sex. We also included a variety of PD disease 
severity measures: maximum levodopa dose (mg/day); use of dopamine agonists; use 
of cholinesterase inhibitors for cognitive improvement (donepezil, galantamine, 
memantine, rivastigmine); and claims for ambulatory devices (e.g., walkers, canes, 
hospital beds, commodes, wheelchairs, and catheters). Finally, the Charlson 
comorbidity index (CCI) was included to capture the general health of each beneficiary 
(60,61). 
Statistical analyses 
Because each Medicare beneficiary could contribute more than one observation 
(person-year) to the dataset, we would expect outcomes to be correlated at the 
beneficiary level, which would violate the standard ordinary least squares assumptions. 
To address this potential problem, we used a generalized estimating equations (GEE) 
approach. GEE techniques have been shown to address correlation for both within-
individual and within-cluster levels (62). For dichotomous outcomes, we assumed a 
binomial distribution and logit link function. For count variables, we used a negative 
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binomial distribution and log link. For the correlation structure, we considered the 
following structures: independent, exchangeable, and unstructured. The choice of 
correlation structure was determined using the quasi-likelihood under the independence 
model criterion (QIC) to determine the best fit (63). Although the lowest QIC across 
model was generally achieved with the independent structure, the exchangeable 
structure had a more plausible set of assumptions and comparably low QIC (within 
0.02%, see Table 7). As such, we conducted all analyses assuming an exchangeable 
correlation structure. 
As noted above, a beneficiary’s decision to participate in a PCMH is likely to be 
endogenous. Thus, we employed a two-stage residual inclusion (2SRI) IV approach 
(64,65). The 2SRI technique uses two regressions to account for endogeneity: a first-
stage regression predicts the likelihood of the endogenous variable (PCMH 
participation) using an IV (PCMH providers per 100,000 Medicare enrollees) and 
controlling for other covariates; the second-stage regression predicts the outcomes of 
interest given the explanatory variable of interest (PCMH participation) while controlling 
for the same covariates and including the residuals from the first stage regression.  
Finally, to estimate robust standard errors accounting for the first-stage regression 
residuals, we used a bootstrapping procedure with 1,000 replications clustered at the 
beneficiary level. Using this approach, we generated both the beta coefficients and 






The study population included 42,640 Medicare beneficiaries with PD and 
depression from 2007 to 2013 (Table 8). These beneficiaries contributed a total of 
69,862 person-years to the analytic dataset. Most of the sample were female and the 
study population was predominantly white (Table 8). This population is older and 
includes fewer minorities than previous studies of PD populations (1,40,47,48), likely 
due to the age of participants (minimum age of 65 years) and exclusion of those with 
Medicaid. Approximately 7.3 percent of the study population (5,098 person-years) had 
at least one visit with a PCMH provider, with average number of PCMH provider visits 
during the entire study period of 7.67 (SD=9.45) visits.  
In naïve (i.e., unadjusted for confounding factors) bivariate tests of associations, 
beneficiaries who participated in PCMH were significantly more likely (p<0.01) to utilize 
most healthcare services, including all hospitalization outcomes of interest. The highly-
significant (p<0.0001) difference in CCI suggests that some health-related selection into 
PCMH is occurring, as enrollees with more comorbidities tended to participate in a 
PCMH. We found no significant differences (p>0.05) in the percentage of enrollees who 
were white, who took dopamine agonists, or who had claims for ambulatory devices 
between PCMH and non-PCMH participants.  
First-stage Results 
The first-stage regression found that number of PCMH providers per 1,000 
Medicare enrollees in the hospital service area strongly predicted PCMH participation 
47 
(χ2 = 2548.06; p<0.0001; Table 9). This suggests that the number of PCMH providers 
per 100,000 Medicare enrollees in the hospital service area is a strong instrument for 
beneficiaries’ PCMH participation. The instrument passes the test of being a strong 
predictor of PCMH participation (67) and can be used in our two-stage estimation to 
control for selection bias. 
Outcomes results 
The second-stage regression estimated the impact of PCMH participation on 
outcomes of interest controlling for selection bias and other confounding factors. 
Coefficients and average marginal effects from the second-stage regressions can be 
seen in Table 10. For quality of depression care, we found that enrollees participating in 
a PCMH were significantly more likely to receive psychotherapy (p<0.01) and less likely 
to receive contraindicated medications (p<0.001). The estimated average marginal 
effect of PCMH participation on psychotherapy was 0.059 (SE=0.023), implying that 
PCMH participation increases the probability of receiving psychotherapy by 5.9 
percentage points. This corresponds to a 33.5% relative increase in psychotherapy use 
compared with those that do not participate in a PCMH. Conversely, enrollees 
participating in PCMH were estimated to have an absolute 7.3% percentage point 
decrease in probability of receiving contraindicated medications, representing a 28.1% 
relative risk reduction compared with enrollees who do not participate in a PCMH. 
PCMH participants were not significantly more likely to receive antidepressant treatment 
for their depression.  
Several of the other covariates had significant relationships with the outcomes of 
interest as well. Age was negatively associated with receipt of these services (P<0.001). 
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Blacks (p<0.001) and Hispanics were significantly less likely to receive outpatient 
services than Whites. Maximum daily levodopa dose, as a marker for severity of PD, 
was significantly (p<0.001) associated with a higher probability of receiving 
psychotherapy. Use of drugs to treat cognitive impairment, claims for DME, and CCI 
score were all associated with a higher likelihood of receiving care as well, to varying 
degrees.  
PCMH participation did not have a significant effect on our health outcomes. The 
average marginal effect was numerically negative (implying a reduced risk of such 
hospitalizations for PCMH participants) for both depression and suicidal ideation. 
However, none of these marginal effects were significantly different from zero at the 
95% confidence level. 
Finally, PCMH participation was also not found to have a significant effect on 
Medicare costs (Table 10). The variance was such that we could strongly discount the 
likelihood that PCMH participation leads to greater costs (p=0.996). 
Discussion 
Using 2SRI with GEE models, we examined the effect of PCMH participation on 
receipt of quality of depression care, risk of depression hospitalizations, and Medicare 
costs among Medicare beneficiaries with PD and major depression. To our knowledge, 
this represents the first study of the effects of PCMH participation in this population. We 
found that PCMH participation significantly increases the likelihood of receiving 
psychotherapy (a relative 33 percent increase in use) and reduces the risk of receiving 
contraindicated medications by a relative 29 percent. Although we observed a numerical 
reduction in risk of hospitalizations for depression and suicidal behavior, neither risk 
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reduction was significant. We also found no significant effect of PCMH participation on 
Medicare costs. 
Our findings suggest that PCMH participation does lead to an improvement in the 
quality of outpatient depression care for Medicare beneficiaries with PD and comorbid 
depression. Increased use of psychotherapy and reduced use of contraindicated 
medications represent direct effects of the PCMH program: improving the process of 
care for patients with complex conditions. No statistically significant effect of PCMH on 
antidepressant use was observed, which may result from already high antidepressant 
use (~80%) consistent with previous studies of elderly individuals with depression and 
comorbid conditions (87,93).  
We did not find significant benefits on hospitalizations for depression or suicidal 
behavior. Research has shown that use of psychotherapy improves health outcomes 
and reduces costs among individuals with depression. As such, we would expect the 
increased use of psychotherapy to improve clinical outcomes. The absence of impact 
on health outcomes may simply result from limited longitudinal sample or from 
depression hospitalization being too severe of an outcome for PCMH care to have an 
effect. We observed an average of approximately 2.3 years of data per enrollee. Thus, 
we likely did not have enough information on the long-term health effects of improved 
care via PCMH participation. An extension of this research could be explored as more 
years of Medicare data become available. Alternatively, one could explore this 
relationship in younger PD patients, for example, those insured by Medicaid. This 
population would be younger and perhaps healthier (earlier in their PD progression) and 
thus potentially more likely to have individuals contributing more years to the sample. 
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However, a Medicaid population would introduce its own set of challenges: transient 
eligibility as individuals move in and out of eligibility throughout a year; differences in 
quality/availability of coverage by state; potential sample size concerns as PD occurs 
more frequently in the elderly; and a younger study population may not adequately 
capture the later and more resource-intensive stages of disease. 
Finally, we did not observe any significant differences in Medicare costs with PCMH 
participation. We would expect greater utilization of healthcare services to result in an 
increase in costs. The nonsignificant difference in costs may suggest that beneficiaries 
are gaining reductions in other medical costs to offset the increase in costs for 
outpatient psychotherapy. Further research into the cost offsets would help illustrate the 
ways in which PCMH care is able to remain cost neutral to Medicare within this 
population. 
The results of this study have substantial policy implications. The significant 
increase in use of psychotherapy and reduction in the use of contraindicated 
medications suggest that the PCMH model may be an effective approach for managing 
depression in those with PD and comorbid depression. The significant effect of PCMH 
on outpatient care is especially impressive given the relatively short time horizon of the 
study.  Policymakers and health care plans may benefit from steering more 
beneficiaries with PD and comorbid depression towards receiving care from a PCMH 
provider. A potential extension of this study would be to further analyze the 
heterogeneity of the PCMH treatment effect within this patient population based on 
specific beneficiary characteristics. This would aid decision makers in identifying 
characteristics of beneficiaries who may benefit most from PCMH care, which may help 
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identify avenues for outreach programs to improve the care for more individuals with PD 
and depression.  
Our study is subject to some limitations. We have noted above the concerns related 
to the definition of PCMH participation and the limited longitudinal information per 
enrollee. An additional limitation relates to the definition of PCMH participation in our 
study. We attributed PCMH participation each year to those individuals with any claims 
with a PCMH provider during the year, which could result in a substantial number of 
individuals with a single visit to a PCMH provider. We found that beneficiaries who 
visited a PCMH provider did so on average nearly 8 times during the study period, or 
over 3 times per year, suggesting that on average we are seeing the value of 
longitudinal PCMH participation. However, as over 20 percent of PCMH participants had 
just one visit to a PCMH provider, suggesting that the effects seen in this study may be 
underestimated. It would be worthwhile to explore the effects of dose intensity on the 
results, examining differences in PCMH benefits as a function of number of visits to a 
PCMH provider. Additionally, if enough variation exists, we could consider the effects of 
the level of PCMH recognition on outcomes.  
Two additional limitations arise with the use IVs: (1) with a single instrument, there 
is no statistical test that can inform us if the instrument is correlated with model 
variables other than theoretical assumption and (2) the results generated are the local 
average treatment effect (LATE); thus, we cannot determine the overall average 
treatment effect (ATE), as we are unable to identify those who would always participate 
or never participate. From a policy perspective, either the ATE or LATE may be of 
interest, but we observe only the LATE in this approach.  
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Finally, we do not have any information on the severity of depression within the 
population. Ideally, measures such as the Hamilton Depression Rating Scale or the 
Montgomery-Asberg Depression Rating Scale would be used, but these are not 
available within claims data (94,95).  
The results of this study suggest that PCMH may benefit Medicare beneficiaries 
with PD and comorbid depression. Specifically, Medicare beneficiaries enrolling in a 
PCMH were significantly more likely to receive psychotherapy and significantly less 
likely to receive contraindicated medications that block dopamine receptors. Our results 
illustrate the value of PCMH care for these individuals with complex health conditions 
and suggest that a coordinated, multidisciplinary, patient-focused model of care may 
lead to higher quality of care and improved health outcomes – and without a significant 
increase in costs - for patients with PD and depression.  
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Tables 
Table 6. Codes used to define clinical covariates 
Parameter P 
Study population  
Parkinson’s disease Any inpatient, outpatient, or carrier claim with ICD-9 code 
332.0 
Depression At least on IP, SNF, HHA, HOP or carrier claim with DX 
codes during the 1-yr period, ICD-9 code 296.20, 296.21, 
296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 
296.32, 296.33, 296.34, 296.35, 296.36, 296.51, 296.52, 
296.53, 296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 
296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 309.1, 
311 
Outcomes  
Psychotherapy HCPCS codes 90785, 90804-90815, 90832-90834, 90836-
90839, 90845-90847, 90849, 90853, 90855, 90857, 90940, 
H0004, H0037, H2017, H2019, H2020, H2033, RC513, 
RC900, RC906, RC909, RC910, RC915, RC919, S9480, 
S9482, S9484, S9485, Y2062, Y2071, Y2080, Y2302, Y2306, 
Y2308, Y2309, Y2313, Y2316, Y2318, YP831-YP834 




Part D claims for: any antipsychotics other than quetiapine or 
clozapine; meperidine if taking a MAO-B inhibitor; droperidol, 
tramadol, methadone, propoxyphene, cyclobenzaprine, 
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halothane; prochlormethazine, metoclopramide, 
promethazine, droperidol; amoxapine 
Hospitalization for 
depression 
Inpatient claims with ICD-9 code 296.2, 296.3, 300.4, or 311 
Hospitalization for suicidal 
behavior 
Inpatient claims with ICD-9 code E950-959, 965.xx, 967.xx, 
969.xx, and 881.xx 




Part D claims for donepezil, galantamine, memantine, 
rivastigmine 
DME for ambulatory 
assistance 
DME claims E0100-E109, E0130-0139, E0160-E0179, 
E0250-E0379, E0950-E1299 
Dopamine agonists Part D claims for apomorphine, bromocriptine, cabergoline, 
ciladopa, dihydrexidine, dinapsoline, doxanthrine, epicriptine, 
lisuride, pergolide, piribedil, pramipexole, 
porphylnorapomorphine, quinagolide, ropinirole, rotigotine, or 
sumanirole 
DME = durable medical equipment; ICD-9 = International Classification of Diseases, 9th Revision; HHA = 
home health agency; HOP = hospice; MAO-B = monoamine oxidase B; SNF = skilled nursing facility; 
WHO ATC/DDD = World Health Organization Anatomical Therapeutic Classification defined daily dose. 
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Table 7. Results of the quasi-likelihood under the independence model criterion 
test 
Correlation Structure Independent Exchangeable Unstructured 
First stage regression 
(PCMH participation) 
28,057.001 28,068.246 28,101.099 
Second-stage regression:    
Psychotherapy 64,092.122 64,267.896 Estimates 
diverging 
Antidepressant use 68,344.187 68,394.605 68,398.041 
Contraindicated 
medications 
76,724.644 76,734.331 76,733.231 
Hospitalized depression 65,683.091 65,683.731 65,683.782 
Hospitalized suicidal 
behavior 
13,472.080 13,472.027 13,472.983 
Medicare costs 1,562,393.065 1,562,429.467 1,562,430.267 
Values presented are the QIC values for each regression model. The “first stage” row refers to the first-
stage regression predicting PCMH use. The remaining 7 rows represent the various second-stage 
regressions for each outcome of interest. 
PCMH = patient-centered medical home; QIC = quasi-likelihood under the independence model criterion. 
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Table 8. Summary Statistics 
Parameter 
Full Sample 
(N = 69862) 
PCMH 
(N = 5,098) 
Non-PCMH 
(N = 64,764) Significance 
Dependent variables     
Psychotherapy use: % 18.1% 23.8% 17.6% p<0.0001 
Antidepressant use: % 79.5% 80.6% 79.4% p=0.0002 
Contraindicated medication 
use: % 
25.6% 20.9% 26.0% p=0.0052 
Number of hospitalizations per 
year: mean (SD) 
    
Depression 0.17 (0.52) 0.17 (0.55) 0.168 
(0.052) 
p<0.0001 
Suicidal behavior 0.020 (0.16) 0.0027 
(0.19) 
0.019 (0.16) p<0.0001 
Medicare costs $30,023.80 $35,042.38 $29,629.77 p<0.0001 
Key explanatory variable/IV     
PCMH participation: % 7.3% 100.0% 0.0% N/A 
PCMH providers per 1,000: 
mean (SD) 
0.385 (0.92) 1.70 (1.69) 0.28 (0.73) p<0.0001 
Control variables     
Age (years): mean (SD) 79.4 (7.4) 79.0 (7.4) 79.4 (7.4) p=0.0002 
Male: % 43.2% 46.5% 49.5% p<0.0001 
Race: %     
White/Caucasian 95.9% 95.8% 95.9% p=0.9115 
Black 2.0% 2.4% 2.0% p=0.0316 
Hispanic 0.5% 0.4% 0.5% p=0.0357 
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Asian 0.5% 0.3% 0.5% p=0.0357 
Native American/Pacific 
Islander 
0.2% 0.0% 0.2% p=0.0025 
Other 0.7% 1.0% 0.7% p=0.1850 









Dopamine agonist use: % 12.4% 11.5% 12.4% p=0.0635 
Cholinesterase inhibitor use: 
% 
29.8% 28.0% 30.0% p=0.0032 
Ambulatory device claims: % 17.9% 17.9% 17.9% p=0.9622 
Charlson comorbidity index: 
mean: SD 
2.37 (2.11) 2.60 (2.25) 2.34 (2.10) p<0.0001 
Year: %     
2007 (year=0) 10.8% 0% 11.6% p<0.0001 
2008 12.0% 0.2% 13.0% p<0.0001 
2009 12.4% 2.1% 13.2% p<0.0001 
2010 13.3% 7.6% 13.7% p<0.0001 
2011 14.8% 15.9% 14.7% p=0.0238 
2012 16.6% 28.9% 15.6% p<0.0001 
2013 20.1% 45.3% 18.2% p<0.0001 
All data are presented at the beneficiary-year level. 
SD = standard deviation. 
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Table 9. First-stage regression coefficients for predicting PCMH participation 
Parameter Coefficient Standard Error P-Value 
PCMH providers per 100,000 
Medicare beneficiaries 
0.6216 0.0072 <0.001 
Age (years) -0.0049 0.0015 0.001 
Male -0.0459 0.0221 0.038 
Race    
Black -0.1004 0.0627 0.110 
Hispanic -0.6142 0.1774 0.001 
Asian -0.5511 0.1551 <0.001 
Native -1.499 0.5705 0.009 
Other -0.2326 0.1085 0.032 
Maximum daily levodopa dose 0.0001 0.0000 0.068 
Dopamine agonist use 0.0165 0.0307 0.592 
Cholinesterase inhibitor use -0.0221 0.0241 0.360 
Ambulatory devices 0.1649 0.0270 <0.001 
Charlson comorbidity index 0.0647 0.0045 <0.001 
Year 1.638 0.0450 <0.001 
Year squared -0.1448 0.0050 <0.001 
PCMH = patient-centered medical home. 
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Outpatient results      
Psychotherapy 0.395 0.142 0.059 0.023 0.009 
Contraindicated 
medication use 
-0.436 0.129 -0.073 0.020 <0.001 
Antidepressant use 0.111 0.102 0.018 0.016 0.259 
Hospitalization results      
Depression  -0.134 0.161 -0.021 0.023 0.355 
Suicidal behavior -0.354 0.403 -0.006 0.007 0.347 
Medicare costs 0.0002 0.049 7.26 1559.5 0.996 
Coefficients are the beta coefficients from the second-stage regression. Average marginal effect is the 
estimated marginal effect of PCMH participation. For outpatient results, the marginal effects represent a 
percentage-point change in the likelihood of receipt of the outpatient service. Hospitalized measures are 
continuous variables, and as such the marginal effect represents the change in number of hospitalizations 
per year associated with PCMH participation. Standard errors and significance level were estimated using 





CHAPTER 5: HETEROGENEITY IN TREATMENT EFFECT 
Overview 
Parkinson’s disease (PD) is a chronic, progressive neurologic disease that affects 
~500,000 elderly Americans. Previous research suggests that patient-centered medical 
homes (PCMH) participation leads to improvements in quality of care and health 
outcomes for Medicare beneficiaries with PD. Given the complexity and heterogeneity 
of the condition, the objective is to estimate the heterogeneity in treatment effect of 
PCMHs among Medicare beneficiaries with PD. To address this objective, we 
conducted a retrospective medical claims database analysis of Medicare beneficiaries 
with PD from 2007 to 2013. A local instrumental variables approach was used to 
estimate person-centered treatment effects of PCMH participation on quality of care 
(outpatient neurologist visits, physical therapy, and speech therapy). These person-
centered treatment (PeT) effects were then used to estimate the average treatment 
effect (ATE), treatment effect on the treated (TT), and treatment effect on the untreated 
(TUT). Additionally, we estimated the difference in treatment effects for different 
observed beneficiary characteristics. Estimating the ATE found that PCMH participation 
led to a 14.68 percentage point increase in receipt of neurologist care, a 15.82 
percentage point increase in receipt of physical therapy, and a 4.34 percentage point 
increase in receipt of speech therapy. Each of these ATE were statistically significant 
(p<0.001). We did observe essential heterogeneity in the effect of PCMH on care and 
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outcomes. Interestingly, we found that the TUT was higher than the TT for physical 
therapy and speech therapy. Heterogeneity was observed across specific 
characteristics as well, although most heterogeneity was not consistent across all 
outcome measures. Notably, Blacks and Hispanics were expected to benefit 
significantly (p<0.001) less from PCMH participation across all outcome measures than 
Whites. Participation in PCMH was found to significantly increase the likelihood of 
receiving outpatient visits with a neurologist, physical/occupational therapy, and speech 
therapy across all characteristics. The heterogeneity in treatment effect suggests that 
PCMH may not adequately address the needs of certain patient groups. While the ATE 
and LATE are important measures of program effectiveness, decision-makers should 
also keep the heterogeneity of treatment effects in mind when developing and/or 
evaluating health care interventions and policies. 
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Introduction and Background 
Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
affecting nearly 500,000 people over the age of 65 in the United States (1). Though 
motor systems such as tremors, bradykinesia, and rigidity are the most well-known 
characteristics of PD, the disease has several non-motor symptoms including sleep 
disorders, fatigue, constipation, sensory dysfunction, cognitive deficits, anxiety, and 
depression (96,97).  
PD is treated through the management of the motor and nonmotor symptoms. 
Outpatient visits with a neurologist, receipt of physical/occupational therapy, and receipt 
of speech therapy have all been found to improve outcomes for individuals with PD (35–
43,47,48). Each of these services have been identified as evidence of good quality of 
care by the American Academy of Neurology (51). But given its complexity and 
heterogeneity, care for patients with PD requires an integrated, multidisciplinary care 
plan with a variety of providers working in concert (10,31–33). 
The patient-centered medical home (PCMH) is a model of healthcare that has been 
broadly defined by the following five attributes (15): (i) Comprehensive care provided 
through a team of care providers including physicians, nurses, pharmacists, 
nutritionists, social workers, and educators; (ii) Patient-centered focus built on 
relationship-based, holistic care of the patient; (iii) Coordinated care in which a strong 
level of communication is fostered between the patient, family, and care providers; (iv) 
Better access to services, including greater hours, 24-hour support via telephone or 
electronic access, shorter waiting times; and (v) Improved quality and safety. The 
National Committee on Quality Assurance (NCQA) introduced standards for PCMH 
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recognition in 2008; their model is the most widely-adopted by practices achieving 
PCMH recognition (19). 
Previous research has found that, after controlling for selection bias and 
confounding factors, PCMH participation leads to a higher probability of seeing a 
neurologist, receiving physical/occupational therapy, and receiving speech therapy (Aim 
1). However, given the difficulty of disentangling selection from actual effects, these 
population-level results may not provide a complete picture of the effect of PCMH on PD 
treatment. IV regression is a useful approach to addressing endogeneity (98), but it has 
limitations. One such limitation is that IV analyses generate a “local average treatment 
effect” (LATE) (99), described as the effect of treatment on those whose decision to 
receive treatment is influenced by the instrument (100,101). More specifically, with a 
dichotomous treatment decision, individuals can be categorized into one of four 
categories: always treated (those who would choose to participate in a PCMH 
regardless of instrument); never treated (those who would never choose PCMH 
participation); and two groups whose decision to participate in PCMH is contingent upon 
the value of the instrument. The LATE does not address the first two categories of 
individual (always/never treated). Thus, the LATE can be considered the treatment 
effect on a “marginal treatment population”. However, we cannot observe which patients 
make up the marginal population (102).  
An additional limitation of IV is that it assumes a homogeneous treatment effect 
(98). However, if there is “essential heterogeneity”, results of a conventional IV 
approach will be biased (100). Figure 1 presents an example of both a homogeneous 
treatment effect and a heterogeneous treatment effect. With a homogeneous treatment 
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effect, the difference between the values for the outcome of interest for the treated 
group compared with the control group is uniform across all individuals. When the 
treatment effect is heterogenous, the difference in outcome varies with some other 
factor (observed or unobserved), such that some individuals experience a greater 
treatment effect than others. In the example in Figure 1, the treatment effect varies with 
age: older individuals experience a greater treatment effect than younger individuals. 
Treatment effects may be positive (treated group experiences more of the outcome of 
interest than the control group) or negative (treated group experiences fewer of the 
outcome than the control group). Similarly, the heterogeneity of effect could be positive 
or negative. 
Modelling techniques can control for heterogeneity of treatment effect when the 
heterogeneity is determined by observable characteristics. However, if the treatment 
effect varies after controlling for observable characteristics (and thus is driven by 
unobserved characteristics), we cannot conveniently model a single estimate for the 
treatment effect. The presence of a heterogeneous treatment effect due to unobserved 
characteristics has been described as essential heterogeneity (100). 
In this study, we examine the heterogeneity in the treatment effect of PCMH 
participation on probability of seeing a neurologist, receiving physical therapy, and 
receiving speech therapy. We hypothesize that there will be significant heterogeneity in 
the treatment effects such that certain individuals will experience a greater treatment 
effect than others. If PCMH is successful in identifying those best suited to benefit from 
PCMH participation, then we would expect the treatment effect in those who selected to 
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participate in PCMH to be greater than the effect for those who do not participate in 
PCMH. 
Empirical Strategy 
To assess the heterogeneity of treatment effect, we apply a local instrumental 
variables (LIV) approach and estimate person-centered treatment (PeT) effects. The 
theory behind the process of estimating PeT effects has been outlined in detail 
elsewhere (103), so we summarize the approach taken here. 
Conceptual framework 
The conceptual framework for this study is as follows. We have a dichotomous 
treatment decision D (in our case, PCMH participation), where D=1 represents the 
beneficiary’s decision to receive treatment from a PCMH provider and D=0 is the 
decision to not go to a PCMH provider. We then assume an outcome of interest, Y (e.g., 
receipt of physical therapy), to be a function of observable covariates Xk, unobservable 
covariates Xu, and a random error term ε: 
Yj = µj(Xk,Xu,ε) 
In this equation, j represents the treatment decision and has a value of 0 or 1. We 
assume that Xk, Xu, and ε are orthogonal. We can also present Y as a function of 
treatment decision D: 
Y = D*Y1 + (1-D)*Y0 
Where Y1 is the estimated value of the outcome of interest when D=1 and Y0 is the 
estimated outcome when D=0. 
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We then assume the treatment decision is a function of the observed covariates and 
an observed instrument that is correlated with the treatment decision but not the 
outcomes: 
D=1 if µD(Xk,Z) – UD >0 
where UD captures all unobserved variables that are correlated with treatment decision. 
We assume UD is of uniform distribution over the range 0 to 1.  
Next, we specify a function P(Xk,Z) estimating an individual’s propensity to choose 
treatment D given a set of known characteristics Xk and an instrument Z. P(Xk,Z) = 
FUd(δD(Xk,Z)). Heckman and colleagues have shown that the marginal treatment effect 
(MTE) can be written as follows (100): 
MTE(x,µD) = δE(Y|Xk,Z)/δP = E((Y1 – Y0)|Xk=x,UD=µD) 
From the information above, D=0 when UD>P(Xk,Z), and D=1 when P(Xk,Z)>UD. 
Thus, the MTE can be described as the treatment effect at the margin where UD = 
P(Xk,Z). In other words, the MTE is the treatment effect for an individual when that 
individual is indifferent toward receiving treatment (103). 
The MTE is critical to estimating person-centered treatment (PeT) effects. Using a 
local instrumental variables (LIV) approach (103), PeT effects are estimated as the 
average MTE for an individual over the range of unobserved characteristics (i.e., the full 
range of UD for that individual). Once we have calculated the PeT, we can calculate 
other treatment effects such as the average treatment effect (ATE), treatment effect on 
the treated (TT), and treatment effect on the untreated (TUT). These can be rewritten as 
follows (100): (i) ATE = E((Y1 – Y0)|Xk=x); (ii) TT = E((Y1 – Y0)|Xk=x,D=1); and (iii) TUT = 
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E((Y1 – Y0)|Xk=x, D=0). A more detailed description of these estimates can be seen in 
Table 11. 
If E((Y1 – Y0)|Xk=x,UD=µD) = E((Y1 – Y0)|Xk=x), then Y is independent of UD given X, 
and MTE = ATE = TT = TUT = LATE. However, if Y is not independent of UD given X, 
then there is essential heterogeneity present in the model, and the treatment effect will 
differ within the population (100). 
Finally, we can use PeT effects to estimate the heterogeneity of the treatment effect 
for specific observed characteristics. By regressing PeT effects as an outcome over a 
set of observed characteristics, we can determine which characteristics which are 
significantly correlated with PeT effect. Individuals with characteristics significantly 
correlated with PeT effect can be said to have greater (if the regression coefficient is 
positive) or lesser (negative) PeT effect. These characteristics would represent those 
characteristics for which individuals would benefit more (if PeT is significantly positive) 
or less (negative) benefit from participation in a PCMH. 
Calculations 
To estimate PeT effects, we first estimate a propensity score estimating the 
probability that a Medicare beneficiary selects to participate in a PCMH. The general 
equation for this is as follows: 
Pit = f(β0 + β1*Xit + β2*Zit + εit) 
Where P represents the propensity to select into PCMH participation as a function 
of a vector (X) of observed characteristics and a vector of instrument(s) (Z). This 
propensity score equation is comparable to running the first-stage regression in a 
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standard instrumental variable approach. As treatment choice is a binary decision, we 
used a logit model for the propensity score regression. 
After deriving the propensity scores for everyone, we developed models of each 
outcome of the following form: 
Yit = f(δ0 + δ1*Xit + δ2*Pit + δ3*XPit + σit) 
where Y represents the outcome of interest, X represents the same vector of 
covariates as in the propensity score model, P represents the propensity scores, and 
XP represents the product of propensity score and each covariate of vector X. As each 
outcome of interest was a dichotomous variable, we again used logistic regression for 
each outcome. 
Once we determined the appropriate specifications for each regression equation, 
we then estimated the MTE for each Medicare beneficiary. This was done by drawing a 
random sampling (500 draws for each beneficiary) over a uniform distribution of UD over 
the range of support of propensity score values for everyone as identified in the first 
stage regression. 
After estimating the MTE for everyone, we then estimated PeT effects by averaging 
the MTE in which UD was greater than the observed propensity score for those treated 
(PCMH participants) and less than the observed propensity score for those not treated. 
Treatment effects were then derived for the population by averaging the PeT effects 
across all individuals (ATE), across those participating in PCMH (TT) and among those 
not participating in PCMH (TUT).  
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Finally, to examine the heterogeneity of treatment effect by covariate, we regressed 
the PeT effects on the covariates from the PeT estimation (i.e., age, sex, race, levodopa 
dose, dopamine agonist use, PD severity, depression, and comorbidities) for individuals 
who experienced a statistically-significant (p<0.05) PeT effect. Standard errors were 
calculated using a bootstrapping procedure with 1,000 iterations. 
Data 
Dataset and study population 
We examined PMCH treatment heterogeneity using medical claims data from a 
nationally representative, longitudinal, 20 percent sample of fee-for-service Medicare 
beneficiaries aged >65 years with medical claims under Part A, B, and D from 2007-
2013. Demographic characteristics and insurance claims at the beneficiary-year level 
for procedures, services, medications, and devices were collected for each beneficiary. 
PD beneficiaries were identified through the presence of a Part A or Part B claim with 
ICD-9 code 332.0X. Exclusion criteria included those eligible for Medicaid at any month 
of the year and those beneficiaries without a Part D claim during the year. All variables 
were measured at the person-year level. 
Outcomes of interest 
The outcomes of interest included outpatient care measures for which a significant 
effect of PCMH has previously been observed (Aim 1): any neurologist visit during the 
year; receipt of physical therapy; and receipt of speech therapy. Each of these services 
represents higher quality of care as stated by the American Academy of Neurology (51) 
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and each has been shown to improve outcomes in PD (35–37,39–43,47,48,50). 
Variable definitions for all outcomes of interest are outlined in Table 12. 
Key explanatory variable and instrument 
The explanatory variable of interest was participation in a PCMH. We defined 
PCMH participation as any outpatient claim with a PCMH provider during the year. As 
noted in our previous study (Aim 1), we found the average number of visits to a PCMH 
provider over the study period to be 7.31 (SD=) visits.  
To estimate the PeT effects, we used a LIV approach (100,103). Our instrument 
predicting PCMH participation was the proportion of PCMH providers per 100,000 
Medicare beneficiaries in the hospital service area. For LIV, three key assumptions are 
needed: (i) the instrument must be continuous; (ii) the instrument is highly correlated 
with the likelihood of PCMH participation; and (iii) the instrument is not otherwise 
correlated with the outcome measures. The instrument is semi-continuous (with a lower 
bound of zero), and we test for significance in the first-stage regression (see results for 
more detail). The third key assumption cannot be tested, and as such we rely on 
theoretical rationale. We would not expect the number of PCMH providers in the area to 
be otherwise correlated with a patient’s health outcomes. 
Control variables 
To control for potential confounding, we included several control variables likely to 
be correlated with healthcare resource use and potentially correlated with PCMH 
participation. These variables included demographic characteristics such as age (in 
years), race/ethnicity and sex. We also included several proxy measures for PD 
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severity: maximum levodopa dose (mg/day); use of dopamine agonists; use of 
cholinesterase inhibitors to treat cognitive impairment; claims for ambulatory devices 
(walkers, canes, hospital beds, commodes, wheelchairs, and catheters). We also 
included two measures of comorbidity to estimate the overall health of the individual: 
presence of depression; and the Charlson comorbidity index (CCI) (60,61). Details on 
the definition for these covariates can be seen in Table 12. 
Results 
Demographic characteristics 
The analysis sample included 103,336 Medicare beneficiaries with PD from 2007 to 
2013 (Table 13). These beneficiaries contributed 238,722 person-years to the analysis 
(~2.3 years per enrollee). Among beneficiaries with PD, 52.2% were male; 94.5% were 
white/Caucasian; and their mean was 79.3 years (7.4 SD). Approximately 5.8% of the 
sample (13,962 person-years) participated in a PCMH.  
In the bivariate analyses, Medicare beneficiaries who participated in PCMH were 
significantly more likely (P<0.01) to use healthcare services and had a higher number of 
comorbidities. The association with CCI suggests that some selection into PCMH is 
occurring, as patients with more severe health concerns are participating in PCMH.  No 
significant differences in PCMH participation were observed in the percentage of 
enrollees who were White or who took medication for cognitive impairment.  
First-stage results 
In our propensity score model, the number of PCMH providers per 1,000 Medicare 
enrollees in the hospital service area strongly predicted PCMH participation (χ2 = 
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7424.25; p<0.0001). The highly-significant correlation between PCMH participation and 
availability of PCMH providers – combined with limited theoretical direct correlation 
between availability of PMCH providers and health outcomes other than through PCMH 
exposure - allows for the use of the number of PCMH providers per 1,000 enrollees as 
an instrument. We found that the entire range of support was covered (0 to 1). 
Population-level treatment effects 
Table 14 presents the ATT, TT, and TUT for PCMH participation on each outcome 
as estimated based on the estimated PeT effects. The ATE was positive for all 
variables, indicating that the average effect of the PCMH was quality-improving. PeT 
effects for the full sample were 0.1468 for neurologist use, 0.1582 for physical therapy, 
and 0.0434 for speech therapy, suggesting that the average benefit of PCMH 
participation is a 14.68 percentage point increase in receipt of neurologist care, a 15.82 
percentage point increase in receipt of physical therapy, and a 4.34 percentage point 
increase in receipt of speech therapy. Each of these ATE were highly statistically 
significant (p<0.001).  
Examining the TT and TUT provides further insight into the effectiveness of PMCH 
programs in identifying the optimal target population. For neurologist use, the TT (17.26 
percentage point benefit of PCMH) was greater than the TUT (14.52 percentage point 
benefit). In other words, PCMH participation was more beneficial to those who 
participated than it would have been for those who did not, indicating efficient selection 
bias. However, the reverse was true for speech therapy and physical therapy: TUT 
(16.09% for physical therapy, 4.45% for speech therapy) was greater than TT (11.42% 
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and 2.61%) in both cases, indicating that those who did not participate in PCMH would 
have benefited more from PCMH than those who did.  
Heterogeneity of treatment effects by individual characteristics 
Significant treatment effects were observed in our three outcomes:  neurologist 
visits, physical/occupational therapy visits, and speech therapy visits, including 
significant relationships between covariates and PeT effects (Table 15). Blacks and 
Hispanics were expected to benefit significantly (p<0.001) less from PCMH participation 
across all three outcome measures than Whites. Blacks had a nearly 50% lower benefit 
from PCMH participation in physical therapy compared with Whites (p<0.001), and both 
Blacks and Hispanics incurred a negative benefit (1-2 percentage point decrease) in 
speech therapy with PCMH participation. Conversely, Native Americans were expected 
to benefit from PCMH participation more so than Whites: 3.21 incremental percentage 
increase in likelihood of seeing a neurologist, 1.64 percentage increase in physical 
therapy, and 29.61 percentage point increase in speech therapy. 
We also observed heterogeneity of PCMH effect in clinical characteristics. 
Beneficiaries on higher doses of levodopa indicating more advanced PD were expected 
to see a significantly larger benefit from PCMH than those at lower doses, although the 
effect was small (0.3 to 1.7 percentage point increase per 100mg increase in daily 
levodopa dose). Conversely, dopamine agonist use was associated with a lower benefit 
of PCMH. While depressed beneficiaries were expected to see a significant (p<0.001) 
benefit from PCMH participation with physical therapy and speech therapy, they were 
not expected to benefit from PCMH participation in receipt of neurologist care. Each 
additional comorbidity was associated with a significantly lower benefit from PCMH 
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across all three measures: -0.28% for neurologist care, -0.99% for physical therapy, and 
-0.55% for speech therapy.  
Discussion 
Using a LIV approach, we explored the heterogeneity in treatment effect of PCMH 
participation on beneficiary’s use of three evidence-based services for adults with PD:  
neurologist visits, physical/occupational therapy, and speech therapy. The LIV approach 
did identify heterogeneity of treatment effect in our study. Interestingly, we did not find 
consistent evidence of optimal sorting: in some cases, those who did not participate in a 
PCMH would have been expected to receive a greater benefit than those who did. For 
both physical therapy and speech therapy, we observed a larger positive effect in 
untreated, rather than treated individuals. Further research is needed to better 
understand why individual selection did not result in maximizing the benefits of these 
services. However, it is worth noting that the ATE, TT, and TUT were found to be 
significantly greater than 0 in nearly all cases, suggesting that PCMH care increases the 
use of neurologists, physical therapy and speech therapy, even if selection has not 
identified the optimal population receiving treatment. 
We also found heterogeneity in treatment effect based on the observable 
demographic and clinical characteristics of the study population. Blacks and Hispanics 
experienced consistently less benefit from PCMH participation than Whites, and in 
some cases were expected to receive no benefit from PCMH participation at all. This 
finding is inconsistent with some previous evidence of PCMH effect on racial/ethnic 
disparities in health care (104,105), and suggests that the PCMH model may not yet be 
addressing the needs of minority groups. Individuals on higher doses of levodopa 
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benefited more from PCMH participation, while those on dopamine agonists benefited 
less, suggesting that individuals with more severe PD may benefit more from PCMH 
participation. Ironically though, we found that each additional comorbidity was 
associated with a decrease in benefit from PCMH participation. This seems 
counterintuitive to the conceptual framework of the PMCH, in that the theoretical value 
for PCMH would be higher for those with complex medical conditions. However, despite 
the observed heterogeneity, the treatment effect of PCMH was still positive for most 
beneficiaries. Only in a few cases noted above did we observe a potentially detrimental 
effect of PCMH participation. 
As with any retrospective secondary data analysis, this study is subject to 
limitations. First, we cannot measure the “intensity” or “quality” of PCMH participation. 
Our measure of PCMH participation is based on a beneficiary having any visits with a 
PCMH provider during the year. Other definitions, such as the modal provider, could be 
used. However, because the complex nature of comorbid PD and depression requires a 
variety of care providers, it is quite possible that the primary care provider is not the 
modal provider for these patients. The average number of visits per PCMH participant 
was 7.31, which translates to an average over 3 visits per year. As such, the identified 
sample of PCMH participants is not likely to be overly dilute with those visiting a PCMH 
provider only once. Still, as over 20 percent of the PCMH sample had just one visit to a 
PCMH provider, it would be worth exploring the effect of dose intensity (i.e., defining 
PCMH participation based on more than one annual visit, such as using a modal 
provider definition) would have in terms of the sorting effects of treatment. Similarly, 
assessing the quality of PCMH may be worthwhile. The NCQA definition of PCMH has 
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three levels of recognition (1, 2, and 3). However, in the research presented here, I only 
considered the impact of PCMH participation as defined by seeing a primary care 
provider that has ANY level of PCMH recognition. Exploring the difference in impact of 
PCMH by level of recognition may provide more insight into the value of the PCMH 
model.  
Additionally, we defined PCMH participation based on identifying visits to providers 
who were recognized by the NCQA. However, there are other agencies from whom 
accreditation could be earned. As such, the results of this study may only be applicable 
to the NCQA definition of PCMH. Furthermore, it is possible that a provider could be of 
comparable quality to NCQA-recognized provider but simply not recognized by NCQA. 
If so, we may be underestimating the benefit of PCMH participation by attributing 
provider status only to those with NCQA recognition. However, it is worth noting that the 
NCQA recognition is the most widely adopted definition of PCMH care in the United 
States, which mitigates the concerns about generalizability and muting of treatment 
effect to some degree.  
Finally, the sample of beneficiaries in this study contributed on average 2.3 years of 
claims data. Parkinson’s disease is a chronic condition that can take many years to fully 
manifest. As such, we may only be capturing a small window of the continuum of care 
for PD with our sample. Further study into the effects of PCMH participation for various 
stages of PD may provide more insight into the value of PCMH care in subsets of the 
overall Medicare PD population. 
This study expands upon previous research into the effects of PCMH care by 
examining the heterogeneity in effects for individuals with PD (Aim 1 and Aim 2). The 
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findings of this study confirm the overall positive effect of PCMH participation on 
outpatient resource utilization for Medicare beneficiaries with PD (Aim 1). Participation 
in PCMH was found to significantly increase the likelihood of receiving outpatient visits 
with a neurologist, physical/occupational therapy, and speech therapy across all 
characteristics. However, in some cases the individuals most likely to benefit were not 
those that participated in a PCMH. Furthermore, the heterogeneity in treatment effect 
suggests that PCMH may not adequately address the needs of certain patient groups. 
While the ATE and LATE are important considerations when assessing the value of a 
program, decisionmakers should also keep the heterogeneity of treatment effects in 
mind when developing and/or evaluating health care interventions and policies. 
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Tables 
Table 11. Examples of Treatment Effects 
Parameter Definition 
Outcome Use of physical therapy 
Treatment PCMH participation 




ATE Difference in probability of using physical therapy among all individuals 
TT Difference in probability of using physical therapy among those participating 
in PCMH 
TUT Difference in probability of using physical therapy among those NOT 
participating in PCMH 
LATE Difference in probability of using physical therapy among those whose 
propensity to participate in a PCMH is a function of the number of PCMH 
providers in the local area 
PeT Difference in probability of using physical therapy for an individual, based 
on observed characteristics, propensity to participate in PCMH (identified 
via instrument), and observed PCMH participation decision 
ATE = average treatment effect; LATE = local average treatment effect; PCMH = patient-centered 
medical home; PeT = patient-centered treatment effect; TT = treatment effect on the treated; TUT = 
treatment effect on the untreated.  
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Table 12. Codes used to define clinical covariates 
Parameter P 
Outcomes  
Neurologist visit Specialty code 13 
Physical/occupational 
therapy 
HCPCS code 97001, 97002, 97003, 97004, 97012, 97016, 
97032, 97110, 97112, 97113, 97116, 97124, 97140, 97150, 
97530, 97537, 97760, or 97761 




Part D claims for donepezil, galantamine, memantine, 
rivastigmine 
DME for ambulatory 
assistance 
E0100-E109, E0130-0139, E0160-E0179, E0250-E0379, 
E0950-E1299 
Dopamine agonists Part D claims for apomorphine, bromocriptine, cabergoline, 
ciladopa, dihydrexidine, dinapsoline, doxanthrine, 
epicriptine, lisuride, pergolide, piribedil, pramipexole, 
porphylnorapomorphine, quinagolide, ropinirole, rotigotine, 
or sumanirole 
















Dependent variables     
Neurologist use (%) 66.2% 74.3% 65.7% p<0.0001 
Physical therapy (%) 12.9% 15.7% 12.8% p=0.0002 
Speech therapy (%) 3.0% 4.1% 2.9% p=0.0052 
Key explanatory variable/IV     
PCMH participation (%) 5.8% 100.0% 0.0% N/A 
PCMH physicians per 1,000: 
mean (SD) 
0.35 (0.88) 1.73 (1.68) 0.27 (0.73) p<0.0001 
Control variables     
Age (years): mean (SD) 79.3 (7.4) 79.1 (7.5) 79.3 (7.4) p=0.0017 
Male (%) 52.2% 53.4% 52.1% p=0.0026 
Race (%)     
White/Caucasian 94.6% 94.6% 94.6% p=0.6416 
Black 2.7% 3.1% 2.7% p=0.0239 
Hispanic 0.6% 0.4% 0.6% p<0.0001 
Asian 0.7% 0.5% 0.7% p=0.0021 
Native American/Pacific 
Islander 
0.2% 0.0% 0.2% p<0.0001 
Other 1.0% 1.1% 1.0% p=0.4457 









Dopamine agonist use (%) 12.6% 11.8% 12.7% p=0.2703 
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Cognitive impairment drug use 
(%) 
22.3% 22.0% 22.3% p=0.0050 
Ambulatory device claims (%) 13.1% 14.1% 13.0% p=0.0003 
Depression (%) 29.3% 36.5% 28.8% p<0.0001 
Charlson comorbidity index: 
mean (SD) 
1.99 (2.01) 2.24 (2.15) 1.97 (2.00) p<0.0001 
Year: %     
2007 (year=0) 12.2% 0% 13.0% p<0.0001 
2008 12.8% 2.0% 13.6% p<0.0001 
2009 12.9% 2.4% 13.8% p<0.0001 
2010 13.5% 8.2% 14.1% p<0.0001 
2011 14.3% 16.6% 14.2% p<0.0001 
2012 15.6% 28.4% 14.7% p<0.0001 
2013 18.6% 44.1% 17.0% p<0.0001 
Mg = milligram; PCMH = patient-centered medical home; SD = standard deviation.  
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ATE = average treatment effect; TT = treatment effect on the treated; TUT = treatment effect on the 
untreated. Sorting effect represents the difference TT – UTT. 
Coefficients (standard errors) presented represent the expected change in outcome resulting from PMCH 














Age 0.0039 (0.0000) 0.0018 (0.0000) -0.0003 (0.0000) 
Male 0.0018 (0.0001) -0.0020 (0.0001) 0.0119 (0.0000) 
Race    
Black -0.0014* (0.0004) -0.0691 (0.0003) -0.0537 (0.0003) 
Hispanic -0.0179 (0.0020) -0.0428 (0.0005) -0.0688 (0.0008) 
Asian 0.0199 (0.0018) -0.1273 (0.0005) 0.1320 (0.0274) 
Native 0.0321* (0.0173) 0.0164* (0.0057) 0.2961 (0.0017) 
Other -0.1401 (0.0094) -0.0343 (0.0003) -0.0332 (0.0002) 
Maximum levodopa 
dose 
0.0034 (0.0000) 0.0169 (0.0000) 0.0047 (0.0000) 
Dopamine agonist -0.0889 (0.0002) -0.0053 (0.0001) -0.0454 (0.0001) 
Cognitive impairment 
meds 
0.0383 (0.0002) 0.0630 (0.0001) -0.0074 (0.0000) 
Ambulatory device -0.0268 (0.0002) 0.0883 (0.0001) 0.0348 (0.0001) 
Depression -0.0024 (0.0002) 0.0305 (0.0001) 0.0067 (0.0001) 
CCI: mean (SD) -0.0028 (0.0000) -0.0099 (0.0000) -0.0055 (0.0000) 
2007 -0.0057 (0.0002) 0.0020 (0.0001) 0.0016 (0.0001) 
2008 -0.0054 (0.0002) 0.0041 (0.0001) 0.0014 (0.0001) 
2009 -0.0024 (0.0002) 0.0032 (0.0001) 0.0012 (0.0001) 
2010 -0.0022 (0.0002) 0.0024 (0.0001) 0.0008 (0.0001) 
2011 -0.0016 (0.0002) 0.0016 (0.0001) 0.0005 (0.0001) 
2012 -0.0006* (0.0002) 0.0003** (0.0001) 0.0002** (0.0001) 
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Constant -0.1550 (0.0008) -0.0503 (0.0004) 0.0610 (0.0002) 
Coefficients (Standard errors) are presented above for regressions of the PeT effect for each outcome of 
interest on key demographic and clinical covariates. Standard errors were derived using a bootstrap 
procedure with 1,000 replications. Significance levels are denoted as * = p<0.01, and ** = p<0.05. All 
other coefficients were significant at the p<0.001 level. 
  
85 
Figure 1. Homogenous and Heterogeneous Treatment Effects 
 
Figure 1 illustrates both a homogeneous and heterogeneous treatment effect. In this example, the solid 
arrow line represents a homogeneous treatment effect for age. The difference between the treatment 
effect for the treated group compared with the control group is uniform across all ages. The dashed 
arrows illustrate a heterogeneous treatment effect for age. The difference in treatment effect varies with 
age, as older individuals experience a greater treatment effect than younger individuals. Treatment 
effects could be positive (treated group experiences more of the outcome of interest than the control 
group) or negative (treated group experiences fewer of the outcome than the control group). Similarly, 





CHAPTER 6: CONCLUSIONS AND POLICY IMPLICATIONS   
Summary of Findings 
In these three studies, I explored the impact of PCMH participation on measures of 
care quality, health outcomes, and expenditures for Medicare beneficiaries with PD. In 
the first study, I considered the impact of PCMH participation on outpatient service 
utilization and, in turn, adverse health outcomes. In the second study, I explored the 
effect of PCMH participation on depression-related outpatient care and adverse health 
outcomes for individuals with PD and comorbid depression. Finally, in the third study, I 
explored the heterogeneity in treatment effect of PCMH participation among individuals 
with PD. 
In the first study, I found that PCMH participation had both a statistically and 
substantively significant effect on the probability of using outpatient services (visiting a 
neurologist, receiving physical therapy, receiving speech therapy). The marginal effect 
of PCMH was a 12.7 percentage point absolute increase in probability of seeing a 
neurologist, 9.6 percentage point increase in probability of receiving physical therapy, 
and 2.8 percentage point probability of receiving physical therapy. For physical therapy 
and speech therapy, these results represent a dramatic impact on utilization: the 
average probability of receiving physical therapy was 12.9% and the probability of 
speech therapy was 3.0%. The estimated effect of PCMH participation on neurologist 
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use was less dramatic, but still represented an ~20% relative increase in probability of 
seeing a neurologist.  
Results were less definitive for hospitalized health outcomes. We observed a strong 
effect of PCMH participation on the risk of falls, with individuals experiencing 1.5 
percentage point lower risk of hospitalization. However, PCMH participation did not 
have a significant effect on the risk of hospitalization aspiration pneumonia. PCMH 
participation did significantly reduce the risk of hospitalization for pneumonia or 
aspiration pneumonia, though, which suggests that perhaps the coding for aspiration 
pneumonia is underreported in hospital claims. 
In the second study, we again found a significant effect of PCMH participation on 
outpatient care for PD beneficiaries with depression. Those participating in PCMH were 
expected to have a 5.9 percentage point increase in probability of using psychotherapy, 
which represents an ~33% relative increase in psychotherapy use. Conversely, PCMH 
participation led to a ~ 33% relative decrease in the probability of receiving a medication 
contraindicated for PD medications. However, we did not find a significant effect on 
hospitalized depression or suicidal behavior; because both are rare events, we may not 
have had a time horizon long enough to capture meaningful differences. Still, the 
increase in utilization of psychotherapy and the decrease in risk of receiving 
contraindicated medicine suggest that PCMH participation improves care for Medicare 
beneficiaries with PD and depression. 
In both study 1 and study 2, the IV approach addressed endogeneity. In both 
populations, PCMH participants had greater comorbidity and, as such, more 
predisposed to adverse health outcomes. When looking at the bivariate relationships 
88 
between PCMH participation and hospital outcomes, I observed a significantly positive 
relationship. After controlling for confounding factors and selection bias with the 2SRI 
approach, I found that PCMH participation generally improved health outcomes instead. 
Interestingly, in both study 1 and study 2 I observed a significant increase in outpatient 
resource utilization. However, in both studies I found no significant difference in 
Medicare costs with PCMH participation. These results suggest that PCMH participation 
increases the use of recommended therapies while remaining cost neutral to Medicare 
within the PD population. 
In study 3, I assessed the heterogeneity of the treatment effect of PCMH 
participation in Medicare beneficiaries with PD. Using a LIV approach, I estimated the 
PeT effects for everyone in the sample. The population-level effect measures were 
interesting: the average treatment effects were similarly favorable for PCMH 
participation; however, the treatment effects on the treated for physical therapy and 
speech therapy were smaller than the treatment effects on the untreated for those same 
outcomes. This suggests that those who might benefit most from PCMH participation 
are not always choosing to participate. Further research is needed to better understand 
the drivers for why optimal patient sorting did not occur. 
Limitations 
The study design above is subject to a few key limitations.  First, claims data lacks 
important characteristics of beneficiaries such as socioeconomic status) disease history, 
and disease severity. There may be underlying patient/disease characteristics that 
could not be controlled for with the data available. It is unclear whether a person with 
such characteristics would be likely to seek enrollment in a medical home, and as such 
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it is unclear the direction (if any) bias was present from the absence of control for such 
variables. As such, I attempted to control for selection bias using an IV approach and 
used proxy variables for key controls such as disease severity. 
Another limitation is that the study is limited to Medicare beneficiaries.  Given that 
the average age of onset for PD is approximately 60, the use of a Medicare population 
is an appropriate choice based on either age or disability status. The Medicare 
population does have limitations in that it may exclude early-onset PD patients, 
especially those with less severe disease who are able to continue to work without 
disability. Medicare beneficiaries are also subject to a lifetime cap on psychiatric 
hospital bed days, which may negatively influence utilization of this resource.  An 
alternative data source would be Medicaid patients or a commercial health plan 
population. Use of either of these populations would require excluding those eligible for 
Medicare, as Medicare will likely account for some of the claims associated with these 
dual-eligible patients.  However, these populations would perhaps result in sample size 
concerns, given that PD is more common in the elderly population. Given the limitations 
of each data source, the Medicare population was chosen to ensure a large enough 
sample size as well as to capture the later stages of disease. 
Policy Implications and Future Research  
In aggregate, results of the three studies suggest that PCMH may be a cost-
effective and potentially cost-neutral model of care for Medicare beneficiaries with PD 
as, after controlling for selection bias, the PCMH appears to provide higher quality 
without increasing costs. As such, policymakers and health care plans may benefit from 
steering more beneficiaries with PD and comorbid depression towards receiving primary 
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care from a PCMH provider. There was heterogeneity in the treatment effect, however; 
as such healthcare decision-makers should identify those individuals for whom PCMH 
participation is expected to provide the most and least benefit. 
Several potential extensions of this work may provide further insights into the value 
of PCMH participation. It would be interesting to explore the effect of PCMH care on 
other health outcomes, such as mortality or institutionalization. As noted in the 
limitations, I would also like to explore the effects of “dose intensity upon the treatment 
effect. Specifically, it would be interesting to explore the impact of number of visits with 
a PCMH provider on outcomes. Additionally, it would be worthwhile to explore the 
differences in the quality of PCMH provider (as a function of NCQA recognition level) on 
outcomes. Another extension of this research could be to examine the effect of PCMH 
participation on individuals in early-stage and/or late-stage disease. Studying the effects 
in other populations, such as a younger cohort via Medicaid or private insurance, might 
allow for more longitudinal data and perhaps provide a richer assessment of health 
outcomes (although sample size could be a concern in a younger population). Finally, 
further research into the cost offsets would also be beneficial to better understand the 
ways in which PCMH care may be able to remain cost neutral to Medicare within this 
population. 
Conclusions  
This study represents an initial exploration of the relationship between PCMH 
participation and care for PD. Using a novel data set constructed for this study, I took a 
comprehensive look at the effects of medical homes on various measures of quality of 
care: outpatient visits, medication adherence, treatment guideline concordance, 
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hospitalization, and costs. Generalized estimating equations modelling was used to 
control for correlation across observations from a common individual, and an 
instrumental variables approach was used to control for the endogeneity of the patient’s 
choice of providers. Using the data and techniques described above, the study provides 
valuable insights into the economic and health implications associated with PCMH 
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